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Background: Computerised cognitive behaviour therapy (cCBT) is an efficient form of therapy potentially
improving access to psychological care. Indirect evidence suggests that the uptake and effectiveness of
cCBT can be increased if facilitated by telephone, but this is not routinely offered in the NHS.
Objectives: To compare the clinical effectiveness and cost-effectiveness of telephone-facilitated free-to-use
cCBT [e.g. MoodGYM (National Institute for Mental Health Research, Australian National University,
Canberra, ACT, Australia)] with minimally supported cCBT.
Design: This study was a multisite, pragmatic, open, two-arm, parallel-group randomised controlled trial
with a concurrent economic evaluation.
Setting: Participants were recruited from GP practices in Bristol, Manchester, Sheffield, Hull and the
north-east of England.
Participants: Potential participants were eligible to participate in the trial if they were adults with
depression scoring ≥ 10 on the Patient Health Questionnaire-9 (PHQ-9).
DOI: 10.3310/hta20890 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 89
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Brabyn et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
vii
Interventions: Participants were randomised using a computer-generated random number sequence to
receive minimally supported cCBT or telephone-facilitated cCBT. Participants continued with usual general
practitioner care.
Main outcome measures: The primary outcome was self-reported symptoms of depression, as assessed
by the PHQ-9 at 4 months post randomisation.
Secondary outcomes: Secondary outcomes were depression at 12 months and anxiety, somatoform
complaints, health utility (as assessed by the European Quality of Life-5 Dimensions questionnaire) and
resource use at 4 and 12 months.
Results: Clinical effectiveness: 182 participants were randomised to minimally supported cCBT and
187 participants to telephone-facilitated cCBT. There was a difference in the severity of depression at 4 and
12 months, with lower levels in the telephone-facilitated group. The odds of no longer being depressed
(defined as a PHQ-9 score of < 10) at 4 months were twice as high in the telephone-facilitated cCBT group
[odds ratio (OR) 2.05, 95% confidence interval (CI) 1.23 to 3.42]. The benefit of telephone-facilitated cCBT
was no longer significant at 12 months (OR 1.63, 95% CI 0.98 to 2.71). At 4 months the between-group
difference in PHQ-9 scores was 1.9 (95% CI 0.5 to 3.3). At 12 months the results still favoured
telephone-facilitated cCBT but were no longer statistically significant, with a difference in PHQ-9 score of
0.9 (95% CI –0.5 to 2.3). When considering the whole follow-up period, telephone-facilitated cCBT was
asssociated with significantly lower PHQ-9 scores than minimally supported cCBT (mean difference –1.41,
95% CI –2.63 to –0.17; p= 0.025). There was a significant improvement in anxiety scores over the trial
period (between-group difference 1.1, 95% CI 0.1 to 2.3; p= 0.037). In the case of somatic complaints
(assessed using the Patient Health Questionnaire-15), there was a borderline statistically significant
difference over the trial period (between-group difference 1.1, 95% CI 0.0 to 1.8; p= 0.051). There were
gains in quality-adjusted life-years at reduced cost when telephone facilitation was added to MoodGYM.
However, the results were subject to uncertainty.
Conclusions: The results showed short-term benefits from the addition of telephone facilitation to cCBT.
The effect was small to moderate and comparable with that of other primary care psychological
interventions. Telephone facilitation should be considered when offering cCBT for depression.
Limitations: Participants’ depression was assessed with the PHQ-9, cCBT use was quite low and there was
a slightly greater than anticipated loss to follow-up.
Future research recommendations: Improve the acceptability of cCBT and its capacity to address
coexisting disorders. Large-scale pragmatic trials of cCBT with bibliotherapy and telephone-based
interventions are required.
Trial registration: Current Controlled Trials ISRCTN55310481.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 20, No. 89.
See the NIHR Journals Library website for further project information.
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Plain English summary
Depression is a common mental health problem. An effective talking treatment for depression iscognitive behaviour therapy (CBT). Computerised CBT (cCBT) is a more recently developed form of
CBT that is delivered with help from a computer rather than a face-to-face therapist. Previous research
indicates that the effectiveness of cCBT can be increased when it is supported with guidance delivered by
telephone. We conducted a fair test of a freely available cCBT program [MoodGYM (National Institute
for Mental Health Research, Australian National University, Canberra, ACT, Australia)] delivered in two
different ways. In the first way, cCBT was delivered with minimal support, as offered in the UK NHS at the
moment. In the second, the same cCBT program was delivered, but in conjunction with weekly telephone
calls providing guidance delivered according to a manual (telephone-facilitated cCBT).
A total of 369 people with depression were allocated either (1) cCBT with minimal support or
(2) telephone-facilitated cCBT. People recruited to the trial completed questionnaires about symptoms of
depression, and general and mental well-being, at 4 and 12 months after the study started.
The telephone facilitation of the cCBT program resulted in additional reductions in depression severity in
the short term, but we were no longer able to detect this effect at 12 months. The provision of telephone
facilitation therefore increases the effectiveness of cCBT. We found that this enhancement of care was
achieved at an acceptable cost and is likely to be good value for money for the NHS. When people with
depression are offered cCBT, they should also be offered telephone support to increase the chances of
deriving benefit.
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Scientific summary
Background
Depression is one of the most common reasons for consulting a general practitioner (GP) and its associated
personal and economic burden is considerable. Although antidepressants remain an important treatment
option, many patients and health-care professionals would like access to psychological therapy as an
alternative or adjunct to drug therapy. Cognitive behaviour therapy (CBT) is the leading evidence-supported
form of brief psychological therapy for people with depression, but the demand for CBT cannot be met with
existing therapist resources. One promising alternative to therapist-delivered CBT that has the potential to
increase access to psychological therapy is the provision of therapy via computers. The National Institute for
Health and Care Excellence (NICE) guidelines recommend the provision of computerised CBT (cCBT)
as an initial lower-intensity treatment for depression as part of a ‘stepped care’ approach in primary care.
Much of the existing evidence for the short-term clinical effectiveness of cCBT for depression comes
from research conducted by the developers of the cCBT programs. National Institute for Health
Research-funded research [the Randomised Evaluation of the Effectiveness and Acceptability of
Computerised Therapy (REEACT) trial] has recently shown that cCBT is no more effective than usual GP
care and is not cost-effective. A possible explanation for the lack of effect is the low level of engagement
with computer technology. Indirect evidence suggests that increasing the level of support that is offered
beyond that which is routinely offered in NHS primary care psychological therapy services might increase
uptake and, in turn, make the technology more effective. However, this has not been tested in a large-scale
pragmatic trial conducted in primary care. The provision of a facilitated self-help program will increase the
costs of cCBT, and the cost-effectiveness of a more intensively facilitated form of cCBT is not known.
If psychological services were to begin routinely to offer cCBT with a higher level of support than is
currently made available, then this should be on the basis of robust evidence of clinical effectiveness and
cost-effectiveness. The REEACT-2 trial examines the potential of guided telephone facilitation to enhance
the uptake and benefit of computer-delivered CBT.
Objectives
This was a fully randomised patient trial to examine the additional benefits of telephone facilitation and
structured guidance alongside a free-to-use computer-delivered CBT package [MoodGYM (National
Institute for Mental Health Research, Australian National University, Canberra, ACT, Australia)]. The
comparator was a minimally supported mode of delivery of the same cCBT package that replicated
the mode of delivery of cCBT, as offered in primary care in the NHS. The REEACT-2 study included a
concurrent economic evaluation to meet the following specific aims:
l to establish the clinical effectiveness of a telephone-facilitated cCBT package compared with minimally
supported cCBT over a 1-year trial follow-up period
l to establish the cost-effectiveness of a telephone-facilitated cCBT package compared with minimally
supported cCBT over a 1-year trial follow-up period.
Methods
Design
This study was a multisite, pragmatic, open, two-arm, parallel-group randomised controlled trial with a
concurrent economic evaluation. The design was a fully randomised comparative trial. Participants were
DOI: 10.3310/hta20890 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 89
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Brabyn et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxi
randomised using simple randomisation with allocation concealed. Treatment allocation and outcome
measurement were not concealed.
Setting
Participants were recruited from UK-based GP practices in Bristol, Manchester, Sheffield, Hull and the
north-east of England.
Participants
Potential participants were identified by (1) direct referral by a GP or health professional attached to a
GP practice or (2) following a written approach by the GP after identification via GP practice database
screening. Potential participants were eligible to participate in the trial if they were aged ≥ 18 years, scored
≥ 10 on a validated depression severity instrument [Patient Health Questionnaire-9 (PHQ-9)] and were not
currently in receipt of cCBT or specialist psychological therapy.
Interventions
Participants were randomised to receive either minimally supported cCBT (MoodGYM alone) or
telephone-facilitated cCBT. Each participant randomised to the telephone-facilitated cCBT arm was
allocated a telephone support worker, who provided weekly telephone calls to (1) facilitate the use of a
cCBT package (MoodGYM) and (2) engage in between-session exercises with problem formulation and
adherence to CBT principles. All participants were also offered usual GP care.
Given the pragmatic design of the trial, no restrictions were imposed on the range of treatments that
could be offered by a GP in either arm. The intervention programme was based on CBT and had been
endorsed at the time of design of REEACT-2 by NICE in the initial treatment of depression in primary care.
The cCBT program involved internet-based, interactive therapy sessions that could be accessed at the
participant’s home, in a central location close to the participant’s home or at the GP practice, depending
on patient preference and availability. All participants were given access to a free telephone helpline,
in addition to which participants allocated to the telephone-facilitated cCBT arm were called on a
weekly basis by a telephone support worker, who delivered structured guidance on the use of the
cCBT program.
Main outcome measures
The primary outcome was depression at 4 months as indicated by a score of ≥ 10 on the PHQ-9.
Secondary outcomes were depression severity at 4 and 12 months (PHQ-9) and anxiety [as assessed by the
Generalised Anxiety Disorder Scale-7 items (GAD-7)], somatoform complaints (as assessed by the PHQ-15),
health state utility (as assessed by the European Quality of Life-5 Dimensions questionnaire) and resource
use at 4 and 12 months.
Results
Clinical effectiveness
One hundred and eighty-two participants were randomised to minimally supported cCBT and 187 participants
were randomised to telephone-facilitated cCBT (MoodGYM). There was a difference in the severity of
depression at 4 months and at 12 months, with lower levels of depression in the telephone-facilitated group.
The odds of no longer being depressed (defined as a PHQ-9 score of < 10) at 4 months were twice as high
in the facilitated cCBT group than in the minimally supported cCBT group [odds ratio (OR) 2.05, 95%
confidence interval (CI) 1.23 to 3.42]. The benefit of telephone-facilitated cCBT was no longer significant at
12 months (OR 1.63, 95% CI 0.98 to 2.71). At 4 months the between-group difference in PHQ-9 scores was
1.9 (95% CI 0.5 to 3.3), with a standardised effect size (Cohen’s d) of 0.32 (p= 0.009). At 12 months, there
was no longer evidence of a between-group difference in PHQ-9 scores (0.9, 95% CI –0.5 to 2.3). Over the
whole trial period, the between-group difference in PHQ-9 scores was 1.4 (95% CI 0.2 to 2.6).
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There was a significant improvement in anxiety scores (GAD-7) when all time points were considered
(between-group difference 1.1, 95% CI 0.1 to 2.3; p= 0.037). In the case of somatic complaints there was
a borderline significant difference when all time points were considered (between-group difference 1.1,
95% CI 0.0 to 1.8; p= 0.051).
Scrutiny of computer records revealed that few participants completed all five sessions of either minimally
supported or telephone-facilitated cCBT, but use was substantially higher among participants offered
telephone facilitation.
Cost-effectiveness
Trial-based cost-effectiveness analyses showed gains in quality-adjusted life-years (QALYs) at a reduced cost
when telephone facilitation was added to MoodGYM, suggesting that this was a dominant enhancement.
In a more conservative sensitivity analysis, telephone facilitation was no longer cost saving but was likely to
be cost-effective at £6933 per additional QALY gained. The addition of telephone facilitation was likely
to be cost-effective at a £20,000 per QALY threshold (probability of cost-effectiveness of 0.55).
Conclusions
Our previous research (REEACT) has demonstrated that minimally supported cCBT is largely ineffective.
Based on the results of REEACT-2, the provision of telephone facilitation appears to offer statistically
significant benefits. Telephone facilitation of a free-to-use cCBT program (MoodGYM) resulted in reduced
depression severity, and reduced the chances of being depressed in the short and medium term. Additional
benefits were seen across secondary outcomes, including anxiety and somatoform complaints. The
magnitude of effect was small to moderate and was comparable with that of other primary care-delivered
psychological interventions. Telephone facilitation represented good value for money (i.e. was well within
conventional thresholds used to determine value for money in the NHS). cCBT is one of a range of effective
low-intensity psychological treatments that can be offered to patients, but only with telephone support.
Minimally supported cCBT (which is routinely offered in the NHS in many services) is likely to be ineffective.
NHS services that currently offer cCBT should consider how best to support this technology, and this will
require sufficient staff being available to offer guidance and facilitation by telephone. The results of the
REEACT-2 study provide a template for telephone facilitation, which the NHS could adopt to deliver
low-intensity psychological therapy at a higher volume.
The magnitude of benefits was modest, but was achieved using a low-cost low-intensity intervention.
Implications for health care
l In this trial for primary care patients with moderate depression, telephone-facilitated cCBT was clinically
effective compared with minimally supported cCBT. Practice recommendations, such as those offered
by NICE, and IAPT (Improving Access to Psychological Therapies) stepped models of care might usefully
be re-examined in the light of these findings with due consideration of the level of support that should
be offered alongside cCBT.
l Minimally supported cCBT (which is routinely offered in the NHS in many services) is ineffective and our
research suggests that it should be offered only when there is sufficient staff in place to support this
technology with guidance and facilitation by telephone. This can be offered by telephone according to
structured delivery manuals, and allows support to be offered at low intensity and higher volume.
l Telephone-facilitated cCBT is likely to be cost saving or cost-effective to the NHS.
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Recommendations for research
l The uptake and use of cCBT was not as high as expected. More research is needed to understand the
reasons for lower uptake and more development is needed for cCBT products to evolve further, such
that they are more acceptable to people with depression. This requires further research and innovation
at the human–computer interface.
l People with depression commonly have coexisting anxiety and somatoform complaints. Although some
benefits were observed in these symptoms, the cCBT materials did not specifically address these
problems. Further research and development is needed to ensure that cCBT products are able to
address coexisting common mental disorders within a single-treatment programme.
l cCBT is a form of self-help. It would be useful to know how cCBT compares with other forms of
guided self-help, since computer-delivered therapy is not acceptable to a significant portion of patients.
Large-scale pragmatic trials of treatments such as bibliotherapy or telephone-based psychological
interventions are therefore needed.
l There is a need to examine the comparative effectiveness of cCBT and traditional face-to-face therapy
in head-to-head trials.
l All effectiveness studies should be framed in primary care and conducted by researchers other than
product developers.
Trial registration
This trial is registered as ISRCTN55310481.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Depression
Depression is the most common mental health disorder in community settings and is estimated to become
the second largest cause of global disability by 2020.1 It is one of the most common reasons for consulting
with a general practitioner (GP) and its associated personal and economic burden is considerable.2
Psychological therapy for depression
Although antidepressants remain an important treatment option, many patients and health-care
professionals would like access to psychological therapy as an alternative or adjunct to drug therapy.3
Cognitive behaviour therapy (CBT) has emerged as the leading evidence-supported form of brief
psychological therapy for people with depression.4,5 However, demand for CBT cannot be met from
existing therapist resources.6 One promising alternative to therapist-delivered CBT is the use of self-help
interventions including the provision of therapy via a computer.7 In recent years a number of interactive
computer programs have been developed that enable CBT to be delivered by a computer. The National
Institute for Health and Care Excellence (NICE) guidelines for depression recommend the provision of
computerised CBT (cCBT) as an initial, lower-intensity treatment for depression as part of a ‘stepped care’
approach in primary care.5 If effective, such programmes have the potential to expand the provision
of psychological therapy in primary care and may represent an efficient and effective form of care
for depression.8
For those who decide to use (or commission the provision of) cCBT there are a number of interactive
internet-based products, some commercially produced and others free to use.7 In the first category, a
number of commercial products have been marketed to bodies such as the NHS. Free-to-use products
comprise a range of programs that have been developed by the public sector or by research institutes.
These can be accessed at no direct purchase cost to health-care providers. An example of a free-to-use
cCBT program is MoodGYM (National Institute for Mental Health Research, Australian National University,
Canberra, ACT, Australia), which was developed in Australia and can be accessed by patients with
depression, either directly or at the suggestion of their health-care provider.
Evidence for computerised cognitive behaviour therapy
Computerised CBT represents an alternative form of therapy delivery that has the potential to enhance access
to psychological care. A number of systematic reviews have been conducted studying the effectiveness of
cCBT. An overall beneficial effect of cCBT has been found within trials, although there is a high level of
variability in effect size between studies. An early health technology assessment review by Kaltenthaler et al.,6
published in 2006, noted preliminary evidence of clinical effectiveness and cost-effectiveness. The authors
noted the existence of internet-based free-to-use packages, such as MoodGYM, which had been evaluated in
randomised trials, but also noted that a major limitation of the existing literature was that the trials had been
conducted by the package developers.8 Since this review there have been few independent evaluations of
cCBT packages and the randomised literature remains dominated by developer-led studies.
Later systematic reviews have also highlighted the potential for cCBT to be effective, but have also further
demonstrated variable effect sizes and substantial between-study heterogeneity.9,10 One important source
of between-study heterogeneity is the level of support that is made available to people who are offered
treatment with cCBT. cCBT involves replacing the therapist with a computer, and requires the person with
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depression to engage with a self-help computer-based technology. Research by Waller and Gilbody11 has
shown that people with depression often do not engage with cCBT, and only a minority actually complete
all of the planned sessions of the computer package. This observation is consistent with a broader body
of research into the uptake and effectiveness across the range of self-help interventions for depression,
including bibliotherapy (self-treatment using written materials). Research in the area of self-help treatments
for depression has demonstrated that entirely self-guided materials (with no professional support) are likely
to be less effective than self-help technologies for which there is a level of guidance and professional
support (‘guided self-help’). Unsupported self-help treatment (including unsupported computer-delivered
self-help) has been shown in systematic reviews to have minimal or relatively small effect sizes. In contrast,
more intensively and professionally supported treatments have generally been found in efficacy trials to
have moderate effect sizes claimed to be comparable to those achieved with face-to-face therapy. To our
knowledge the comparative effectiveness of minimally supported cCBT versus more intensively supported
cCBT has not been directly tested in large-scale, independently conducted, head-to-head effectiveness
trials. Based on indirect estimates drawn from systematic reviews of trials of cCBT the effect is therefore
potentially enhanced through the provision of professional support. The magnitude of benefit associated
with supported cCBT in groups of patients is, on average, larger than that with unsupported/minimally
supported cCBT [pooled effect size for professionally supported therapy, Cohen’s d= 0.61, 95%
confidence interval (CI) 0.45 to 0.77 vs. unsupported therapy, Cohen’s d= 0.25, 95% CI 0.14 to 0.35].9
Existing Health Technology Assessment programme-funded
research into computerised cognitive behaviour therapy for
depression: the results of the REEACT trial and the need
for further research on the effectiveness of supported
computerised cognitive behaviour therapy
On the basis of a UK technology appraisal by Kaltenthaler et al.6 and the identified need for independent
(non-developer-led) research into cCBT, the Randomised Evaluation of the Effectiveness and Acceptability
of Computerised Therapy (REEACT) trial was commissioned in 2008, recruited in 2010–12 and reported in
2015.12 The design of the REEACT trial was to compare the clinical effectiveness and cost-effectiveness
of commercially developed cCBT (Beating the Blues; Ultrasis, London, UK) versus free-to-use cCBT
(MoodGYM) versus usual GP care. The trial was pragmatic in design and recruited 691 participants in UK
primary care. The level of support that was offered to both cCBT packages was designed to replicate
current practice in NHS primary care in which professional facilitation is not routinely offered. In view of
the findings of systematic reviews, and evidence of lower uptake of packages in entirely self-directed/
unsupported therapies, the REEACT trial included technical telephone support. Participants were
proactively offered technical support and weekly encouragement to use the computer packages, but we
purposely did not augment psychological therapy over the telephone. Telephone support in the REEACT
trial did not involve explanations of CBT and did not involve a review of homework or between-session
tasks. The cCBT was therefore a form of supported self-help, but was not one that was guided by a
clinician. The REEACT trial is, at the time of writing, the largest publicly funded, independently conducted
primary care trial of cCBT.
The main finding of the REEACT trial was that for the primary outcome of depression severity at 4 months,
there was no significant benefit when participants were offered technically supported cCBT in addition to
usual GP care. This negative finding was true for both a free-to-use package (MoodGYM) and commercially
produced cCBT (Beating the Blues). The most likely explanatory mechanism of lack of effect was poor
uptake and use of computer packages by trial participants. For both cCBT packages (MoodGYM and
Beating the Blues) the median number of actual computer therapy sessions that were completed by
participants was between 1 and 2. The conclusion of the REEACT trial was that technically supported cCBT
was clinically ineffective when added to usual GP care, and that this treatment should not routinely be
offered in this form to patients with depression.
BACKGROUND
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Preliminary findings from a concurrent qualitative evaluation in REEACT, and anecdotal evidence from
recruiting researchers, indicated that participants were demotivated as a consequence of depression and
struggled to engage with computer sessions despite appreciating the offer of technical support. Participants
expressed an interest in computer packages, but identified a preference for guidance. We postulated
on the basis of these findings and on the basis of emerging trial-based evidence summarised in systematic
reviews (e.g. Andersson and Cuijpers9) that cCBT might show an effect but only if offered alongside a
greater level of facilitation and support and designed the REEACT-2 study to run alongside, but
independently of, REEACT and test this hypothesis. The REEACT-2 trial represents a follow-on trial from the
REEACT trial to answer this related question, and most of the fundamental aspects of trial design (primary
care setting, recruitment process and inclusion criteria) are replicated in the two trials.
Research objectives
This was a fully randomised patient trial to examine the additional benefits of telephone facilitation
alongside a free-to-use computer-delivered CBT package (MoodGYM). The comparator was a minimally
supported mode of delivery of the same cCBT package that replicated the mode of delivery of cCBT as
offered in primary care in the NHS. The REEACT-2 study included a concurrent economic evaluation to
meet the following specific aims:
l to establish the clinical effectiveness of a telephone-facilitated cCBT package compared with minimally
supported cCBT over a 1-year trial follow-up period
l to establish the cost-effectiveness of a telephone-facilitated cCBT package compared with minimally
supported cCBT over a 1-year trial follow-up period.
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Chapter 2 Methods
Trial design
This study was as a multisite, pragmatic, open, two-arm, parallel-group randomised controlled trial.
Participants were recruited from primary care through direct referral by their GP or a postal invitation from
GP records. Participants were individually randomised to one of two arms:
1. minimally supported cCBT
2. telephone-facilitated cCBT.
Participants in both arms were given access to a free-to-use cCBT program (MoodGYM), an accompanying
booklet, and a Freephone number for technical support, and continued with usual GP care. Participants in
the telephone-facilitated cCBT arm were additionally allocated a telephone support worker (TSW) who
provided a programme of weekly telephone calls. The programme is described in more detail in Intervention.
Participants were followed up over the course of 12 months, with data collected at 4 and 12 months
post randomisation.
Approval
Ethics approval was granted by Bradford Research Ethics Committee (10/H1302/95) on 20 December 2010
and from relevant research and development committees. The trial was assigned the International
Standard Randomised Controlled Trial Number (ISRCTN) ISRCTN55310481.
Trial sites
The study was conducted in four UK sites with well-established networks of practices from which to
recruit. These were the Universities of York, Bristol, Sheffield and Manchester.
Participants
The study population included patients in primary care with depression or low mood as determined by a
score of ≥ 10 on the Patient Health Questionnaire-9 (PHQ-9).13 This cut-off point is known to detect clinical
depression (major depression) in a UK primary care population with a sensitivity of 91.7% and a specificity
of 78.3%.
The participants were recruited from a mix of rural and urban GP practices in and around Bristol, Avon,
Somerset, Gloucestershire, Manchester, Sheffield and South Yorkshire, York, Humberside and East
Yorkshire, Durham, Tyneside and Northumberland.
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Inclusion criteria
Participants who met the following criteria were eligible to enter the study:
l aged ≥ 18 years
l not currently in receipt of cCBT or specialist psychological therapy
l score of ≥ 10 overall (indicating moderate, moderately severe or severe depression) and < 3 for item 9
(measuring suicidal thoughts)14 on the PHQ-9 depression severity measure.
Both incident and prevalent cases were included. In line with the pragmatic nature of this trial reflecting
usual GP care, patients were eligible to participate whether or not they were in receipt of antidepressant
medication, and those with comorbid physical illness or non-psychotic functional disorders were
not excluded.
Exclusion criteria
We excluded potential participants who
l were actively suicidal as identified by the GP or as reported by item 9 on the PHQ-9
l had been bereaved within the last year
l had given birth within the last year
l had a diagnosis of psychotic depression
l had a primary diagnosis of alcohol or drug abuse
l were not able to read and write in English.
Participant recruitment
All recruiting researchers were given training in all aspects of the trial including trial recruitment, informed
consent, adverse event reporting procedures, and risk assessment and reporting procedures. Each
researcher was also given a study reference manual with full instructions on all the standard procedures.
Participating GPs were provided with a GP manual with details of the trial processes, a GP information
leaflet, adverse event reporting guidance, information about the interventions and contact details for the
trial team.
Direct referral
Practices taking part in this study were provided with patient information packs containing a cover letter,
patient information sheet, copy of the consent form and a prepaid envelope addressed to the local
researcher, to give to patients with depression who were receptive to participating in the trial. The GP or
representative could complete and fax a referral form and patient permission-to-contact form to the study
researcher who, following a consideration period of at least 2 days, then approached the patient to discuss
the study in more detail and confirm eligibility and continuing interest. The study design and approvals
allowed that other health-care professionals attached to practices, such as nurses or primary care mental
health workers, could refer patients to the study in the same way, but in the event participants were only
referred by GPs.
Participation identification from general practitioner records
General practitioner practices were also asked to conduct a search of their records to identify patients
presenting with depression or low mood, and screen for potentially eligible participants. Patient
information packs supplied by the research team were sent from the GP practice inviting interested
patients to return a completed permission-to-contact form to the research team. A member of the study
team then made contact to confirm eligibility and discuss the study in further detail.
METHODS
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Screening for eligibility
After receiving permission-to-contact forms, the researcher contacted the potential participant to discuss
the study, answer any questions and then confirm that the patient was still interested and eligible.
To assess eligibility the potential participant was asked to confirm that he or she still met the inclusion
criteria, in particular those that may not have been known to the GP, such as bereavement and drug
and alcohol problems. The researcher also ensured that the participant understood what participation
entailed, had access to the internet and wanted to take part in the trial. Participants were then
asked whether they preferred the baseline assessment to be conducted over the telephone or at a
face-to-face interview.
Consenting participants
Potential participants who preferred to have baseline data collected by telephone were asked to return the
signed consent form in the prepaid envelope in the information pack. Those who preferred a face-to-face
interview completed the consent process at the first meeting.
All potential participants were given a full explanation of the study and the opportunity to ask any
questions or discuss concerns. Researchers emphasised that participants could withdraw consent at any
point and would not have to give any explanation nor would their joining the study or leaving it at any
point affect their GP care. Participants were also reminded that by consenting they agreed to their GPs
being informed of their participation. Written informed consent was then taken, both participant and
researcher signing and dating the consent forms and each keeping a copy.
Baseline assessment
Having consented to join the trial, participants completed a series of baseline questionnaires providing
biographical, health status, health state utility and service use data. The participant was then randomly
allocated according to the process outlined below (Figure 1).
Randomisation
Participants were randomly allocated in a ratio of 1 : 1 to one of two treatment conditions: (1) minimally
supported cCBT or (2) telephone-facilitated cCBT. Both conditions included log-in details for a free-to-use
cCBT program (MoodGYM), a booklet accompanying the program, usual GP care, and access to a free
helpline for troubleshooting and general help with the program. Simple randomisation was performed
using a computer-generated random number sequence. The REEACT-2 trial researchers telephoned a
secure randomisation line at the York Trials Unit and were given the participant’s allocation and log-in
details for the MoodGYM program. By default, randomisation was done at the face-to-face interview and
the participant informed immediately and given a copy of the MoodGYM booklet. If the interview finished
after the randomisation line closed, the participant was informed the next day. The researcher then
informed the trial manager who allocated TSWs to participants in the supported cCBT arm.
Sample size
The REEACT-2 trial was powered on the basis of an ability to detect a between-group difference in
depression severity. We sought to recruit 350 patients with depression – 175 participants per arm. The
REEACT-2 trial was designed to have sufficient power to detect a Cohen’s d effect size of 0.30 with 80%
power (one-sided 5% significance level) allowing for loss to follow-up of 20%, in line with our empirically
based estimates from the REEACT trial. The final sample size for the two arms was 369 participants.
Intervention
In line with the template for intervention description and replication (TIDier)15 guidelines the intervention is
described below using the prescribed checklist headings.
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• Potentially eligible patients are 
   approached by their HCP as they 
   present to practice
• If patient is interested in taking part
   the patient completes a permission-
   for-researcher contact form. The HCP
   completes a referral checklist
• The HCP faxes both forms to the local
   researcher and provides the patient 
   with an invitation-to-participate letter,
   a patient information sheet, consent
   form and prepaid envelope
Direct HCP referral
• At least 48 hours after receiving the
   permission-to-contact form, the 
   researcher contacts the patient to 
   discuss the study further
Patients are identified by their GP practice through either direct referral or a recording screening method
• GP records are searched for potentially
   eligible patients using a Read 
   code algorithm
• List of potential participants screened
   by GPs to ensure appropriateness of 
   study invite
• Potentially eligible patients sent a 
   recruitment pack from the practice 
   including an invitation-to-participate 
   letter, a patient information sheet, 
   consent form, permission-for-researcher
   contact form and a prepaid envelope
Record screening approach
• Patient returns permission-to-contact 
   form and consent form to researcher 
   in prepaid envelope provided
• Researcher contacts the patient to 
   discuss the study further
Only proceed with baseline 
questions once consent form has 
been returned
Baseline PHQ-9 conducted
• Patient no longer interested in 
   participating
• Identifiable information removed from
   study database
• No further contact with the patient
• Informed consent confirmed by
   researcher
• Researcher completes brief screening 
   questions to check for eligibility
• Researcher completes brief screening 
   questions to check for eligibility
• Patient thanked for their time
• Identifiable information removed from 
   study database
• No further contact with patient
• GP informed of outcome of referral
• Suitable time arranged with patient 
   to complete baseline questions 
   over telephone
• Post confirmation of telephone 
   appointment letter and baseline 
   questionnaire guide
• Alternatively, researcher arranges a 
   face-to-face interview
• Patient asked to return consent form if 
   they have not already done so
• Suitable time arranged with patient to 
   complete baseline questions over 
   telephone – allow sufficient time if 
   consent form has not yet been returned
• Post confirmation of telephone 
   appointment letter and baseline 
   questionnaire guide
• Alternatively, researcher arranges a 
   face-to-face interview
Ineligible
• 4 months: follow-up questionnaires completed either by postal questionnaire, telephone interview, 
   online or face-to-face interview
• 12 months: follow-up questionnaires; same choice of methods as before
Follow-up
Withdrawal 
At any point during the study participants can choose to withdraw consent
EligibleEligible
• Scored < 10 on PHQ-9 in total or 3 on 
   question 9
• Patient thanked for their time
• Identifiable information removed from 
   study database
• Activate suicide protocol as appropriate
• No further contact with patient 
• GP informed of outcome of referral
• Scored > 10 on PHQ-9 in total and < 3 on
   question 9
• Continue with the rest of the baseline 
   questionnaires
• Randomise and inform participant of 
   allocation
• GP informed of outcome
IneligibleEligible
• Provided with access details for 
   cCBT program
• Provided with freephone helpline
• Participants work through cCBT 
   program either at home or at a 
   central location. Expected to 
   take 6–8 weeks
• Provided with access details for cCBT 
   program
• Provided with freephone helpline
• TSW contacts participant to arrange 
   weekly calls
• Participants work through cCBT 
   program either at home or at a central
   location. Expected to take 6–8 weeks
Telephone-facilitated cCBT groupMinimally supported cCBT group
FIGURE 1 Flow of recruitment to the trial. HCP, health-care professional.
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Rationale
This trial built on preliminary findings from the REEACT trial (ISRCTN91947481). In the REEACT trial, we
found that participants were not always keen to engage with the cCBT programs, and they expressed a
desire to receive a greater level of support. Participants were happy to receive this support over the
telephone, but felt that this should reflect and emphasise the practical elements of CBT. One way to
encourage engagement with self-help technologies is to offer complementary low-intensity support by
telephone.16 The REEACT-2 study was designed to examine if a programme of structured telephone
facilitation would enhance engagement with the MoodGYM program and whether or not enhanced
engagement would lead to better outcomes. The telephone-facilitation programme was designed to be
capable of delivery by appropriately trained and supervised individuals who are not necessarily people with
a professional background in mental health. The support programme was designed to be delivered after a
brief structured training programme and with reference to a treatment manual.
Materials
MoodGYM is a free-to-use, internet-based, interactive CBT program for depression, developed and
copyrighted at the Australian National University Centre for Mental Health Research. The online program is
accompanied by a booklet with exercises and quizzes, and consists of five interactive modules released
sequentially and lasting approximately 30–45 minutes and a sixth session that is predominantly
consolidation and revision. Study participants were asked to aim to complete one session each week.
The program provides patients with CBT techniques to overcome patterns of unhelpful thinking using
cartoon characters to represent habits of thought.17
Procedures
Experimental intervention: weekly supportive/facilitative telephone calls plus cCBT (telephone-
facilitated cCBT).
Participants in the experimental group received regular (ideally weekly) telephone calls from a trained
worker to offer support, guidance and encouragement.
The telephone facilitation programme comprised eight telephone calls to be completed alongside the cCBT
program within the 12–14 weeks between the first contact from the TSW and the 4-month follow-up time
point. The purpose of the first and longest session (30–40 minutes) was to introduce the participant to the
principles of CBT and the MoodGYM program and booklet, explain the process and help the participant
identify difficulties and goals, and feel confident about engaging with the intervention.
The following six sessions were between 10 and 20 minutes long and were intended to provide motivation and
to help participants identify any barriers to engagement and to the achievement of their goal(s). The final session
helped participants to consolidate what they had learned and discussed their next steps and, if appropriate, how
they might use the program in the future. The telephone-facilitation programme was delivered according to a
manual developed by Professor Karina Lovell in conjunction with the REEACT-2 trial team.
Comparator intervention: minimally supported computerised cognitive
behaviour therapy
All patients in the control group were registered as users of MoodGYM and given a unique password.
As with the intervention group, they were supplied with a free helpline number to ring if they had
technical problems or needed advice, but they did not receive regular telephone calls. This comparator
intervention replicates NHS care in most settings and represents what would happen if a patient were
given the website of a cCBT package such as MoodGYM by their GP or primary care mental health worker
without being offered proactive support.
Providers
The intervention was delivered by TSWs, a team of people specifically recruited to support the REEACT-2
trial and trained in the delivery of the manualised telephone facilitation intervention. The support workers
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were not recruited to act as psychotherapists to the participant and were not instructed to replicate or
consolidate the therapeutic content of the packages, as they were not trained or instructed to act as
cognitive behaviour therapists.
The professional background was mixed and included psychology graduates and people who
demonstrated good interpersonal skills who had worked as counsellors, social workers, psychiatric nurses
and volunteers with mental health charities (e.g. Samaritans). The telephone facilitation programme
was delivered according to a manual developed for the REEACT-2 trial. Full training in delivery of the
programme, including the management of information that may be troubling or indicate risk, was given to
all potential TSWs and their suitability to take on the role was assessed during the training and with
recorded mock facilitation sessions with an experienced TSW.
Follow-up training meetings took place during the trial on a roughly bimonthly basis and TSWs had access
at all times by telephone to a supervisor with a professional background in mental health (KL, mental
health nursing; DK, primary care physician; and SG, psychiatrist). Between training meetings with KL,
regular contact was maintained with the trial manager via e-mail and telephone. TSWs were provided
with continuing case supervision every 2 weeks from the trial manager who managed the majority of
day-to-day queries. Sessions with participants were recorded (with consent) and early sessions were
monitored by a senior trial principal investigator for fidelity to the manual.
Mode of delivery
Participants were given a copy of the MoodGYM booklet at the baseline interview and the MoodGYM
program was generally delivered via participants’ own internet-connected computer, enabling participants
to log on at their convenience. The default mode of delivery of the support programme was via the
telephone. Three participants requested an alternative mode of communication (e-mail) because they felt
too anxious to use the telephone.
Locations
Participants could log on to the MoodGYM application anywhere with broadband internet access. They
were encouraged to make sure that they had a suitable environment for an appropriate length of time.
Researchers could help participants to identify and book time at alternative locations with computer access
such as public libraries or GP practices if they had no internet access at home or their home was not a
suitable location for any reason.
Participants were encouraged to be at home, or somewhere comfortable and private for the telephone
appointments. Whatever the location, to maintain privacy, the participant and TSW agreed a code word in
the first session that the participant could use to indicate that it was not appropriate to continue with the
conversation and that they would reconvene later.
When/how much
The TSWs contacted the participants at pre-arranged times to suit, as far as possible, the participant.
This included some weekend and evening calls. The intervention provided eight telephone calls. The first
of these was expected to last between 30 and 45 minutes, the following seven calls between 10 and
15 minutes, and the final call 20 minutes.
Tailoring
Telephone support workers worked to a manual but their conversations were not scripted. The telephone
support programme could be tailored to some extent because there was some variation in the severity of
participants’ depression, their availability and their willingness or ability to complete a module each week.
Adherence
Adherence by participants to the computer program was measured by requesting information from the
website providing MoodGYM (hosted by the developers of MoodGYM at the Australian National
METHODS
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University, Canberra, ACT, Australia). We obtained computer usage data on the number of times each
participant logged on to the MoodGYM program and whether or not each module was 25%, 50%,
75% or 100% complete.
Telephone support workers kept records of the number and length of telephone sessions as well as
detailed records of all attempts to contact the participants.
Fidelity
Fidelity to the telephone support manual was monitored in supervision discussion and from the recordings
of the sessions. In keeping with the pragmatic nature of the trial there was a certain amount of variation in
the delivery between TSWs and between participants. Telephone sessions were not formally scrutinised or
analysed as a research activity, but the recordings have been retained for future reference.
Outcomes
Primary outcome measure
The primary outcome was depression severity and symptomatology as measured by a validated self-report
measure (the PHQ-9)14 at 4 months because this is the point at which the largest between-group
difference might be expected. The PHQ-9 logs the core symptoms of depression and takes the form of a
questionnaire comprising nine sections.
Data were collected in one of four ways according to participant preference:
1. by telephone interview with a recruiting researcher
2. completion of a client report form (CRF) sent out by post
3. online
4. at a face-to-face interview with a recruiting researcher.
Secondary outcome measures
The secondary outcome measures comprised the PHQ-9 at 12 months, anxiety [as measured by the
Generalised Anxiety Disorder Scale-7 items (GAD-7)];18 somatoform complaints [as measured by the Patient
Health Questionnaire-15 (PHQ-15)];19 health state utility [as measured by the European Quality of Life-5
Dimensions (EQ-5D)];20 and service use using the adapted Client Service Receipt Inventory (CSRI)21 and
Client Satisfaction Questionnaire-8 items.22 The secondary outcome measures were recorded at 4 and
12 months. A summary of assessments and data collection time points can be found in Table 1.
Statistical analysis methods
Analyses were performed using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA) on a two-sided basis
and using a 5% significance level.
Primary analysis
All outcomes were summarised descriptively by intervention group and at each time point using mean,
median, standard deviation (SD), range and number of patients for continuous outcomes, and number of
patients and percentage for discrete outcomes.
Patient Health Questionnaire-9 at 4 months
The primary outcome was the severity of depression as measured by the PHQ-9 at 4 months, a self-reported
questionnaire. The primary analysis used the PHQ-9 score as a dichotomous outcome with a score of
≥ 10 meaning depressed and < 10 not depressed; a cut-off point of 10 has been shown to be sensitive for
detecting clinical depression in UK primary care.25 The PHQ-9 is a nine-item questionnaire that records the
core symptoms of depression and gives a total score ranging from 0 to 27, with a higher score indicating
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more severe depression. It is categorised as follows: 0–4, none to minimal depression; 5–9, mild depression;
10–14, moderate depression; 15–19, moderately severe depression; and 20–27, severe depression. The
cut-off point of 10 was used to categorise participants as depressed or not depressed at 4 and 12 months
(PHQ-9 score of ≥ 10 depressed, PHQ-9 score of < 10 not depressed). To be included in the study,
participants had to score of ≥ 10 on the PHQ-9 at baseline. The PHQ-9 score at each time point was
calculated as the sum of all nine items. If one item was missing it was replaced with the mean of the other
eight, but if two or more items were missing, then the whole questionnaire was treated as missing (using
the same scoring method used in the REEACT trial).
The number and percentage of participants who were not depressed/depressed were reported at 4 and
12 months and treatment groups were compared using a chi-squared test. The missing responses were
summarised and possible reasons explored by summarising and comparing baseline data between those
with and without a missing outcome. The primary analysis compared minimally supported cCBT with
telephone-facilitated cCBT using a logistic regression model adjusting for the baseline PHQ-9 score, age,
sex, baseline GAD-7 score and treatment. Odds ratios (ORs) with 95% CIs are reported.
The primary analysis was on a complete case basis (only including those with a 4-month assessment).
As some missing data were expected, sensitivity analyses were performed using imputation. A simple
imputation on a worst-case scenario was used assuming that all participants with a missing outcome were
still depressed. Anyone with a missing PHQ-9 score was assumed still to be depressed and have a score
of ≥ 10.
TABLE 1 Assessments and time points at which they were carried out
Assessment
Time point
Baseline 4 months 12 months
Eligibility and consent
Eligibility ✗
Consent ✗
Background and follow-up
Personal details ✗
Education ✗
Employment status ✗ ✗
Marital status/living arrangements ✗
Previous episodes of depression ✗ ✗ ✗
Current antidepressant medication use ✗ ✗ ✗
Questionnaires
PHQ-914 ✗ ✗ ✗
Anxiety (GAD-7)18 ✗ ✗ ✗
Somatoform symptoms (PHQ-15)19 ✗ ✗ ✗
Health state utility (EQ-5D)20 ✗ ✗ ✗
Health economics/service utilisation questionnaire (adapted CSRI)21 ✗ ✗ ✗
Client satisfaction survey (CSQ-8)22 ✗ ✗ ✗
Need for affect23 ✗
Self-efficacy24 ✗
CSQ-8, Client Satisfaction Questionnaire-8 items.
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Secondary analyses
Patient Health Questionnaire-9 at 12 months
The secondary analysis of the primary outcome was the same as for the primary analysis but used the
PHQ-9 score of < 10/≥ 10 (not depressed/depressed) at 12 months.
Patient Health Questionnaire-9 as a continuous outcome
The PHQ-9 score was also summarised and analysed as a continuous outcome. This is summarised for each
assessment time point (baseline, 4 and 12 months) using mean, SD, median and range, and the number
of missing values. Plots are presented showing the mean and 95% CI at each time point.
Means and SDs at the previous assessment were summarised and compared between those with and
without the subsequent PHQ-9 score missing, using t-tests, to evaluate whether or not there were
differences in scores between those with and without a missing assessment (i.e. whether or not those who
dropped out were more depressed).
A repeated measures mixed regression model was used to analyse the change in PHQ-9 score over time.
This included all randomised participants and provides reliable estimates assuming the data are missing at
random. The outcome was the PHQ-9 score at 4 and 12 months and the model included the baseline
score, treatment, age, sex, baseline GAD-7 score and time. The treatment × time interaction was included
to evaluate if the difference between treatments changed over time. Different covariance structures were
evaluated (e.g. unstructured, compound symmetry) and the one providing the best fit was used. Residual
plots were used to check model assumptions. The mean difference, 95% CI and p-values are presented for
all terms in the model. Effect sizes (Cohen’s d) were calculated for the between-group differences in mean
PHQ-9 score at 4 and 12 months using the difference between the means and corresponding standard
errors from the mixed model. The standard errors were converted to SDs using the corresponding sample
size in each treatment group.
Other secondary outcomes
The GAD-7 and PHQ-15 scores were analysed as continuous outcomes using the same repeated measures
mixed models, as described for PHQ-9 above.
The number of participants taking any medication to help with their depression was summarised
descriptively at each time point. cCBT use was summarised descriptively.
Adverse events
Adverse event data were summarised descriptively.
Economic methods
The primary objective of the economic analysis was to assess the relative cost-effectiveness of
telephone-facilitated cCBT compared with minimally supported cCBT. The economic analysis was
conducted prospectively alongside the REEACT-2 trial.
Health-related quality of life
Decisions concerning resource allocation often need to be taken across specialties and disease areas.
If these decisions are to be informed by a cost-effectiveness analysis, then it is crucial that the outcome
measure adopted is generic (i.e. that it has meaning outside the clinical area within which it is used).
The use of a single generic measure of health benefit enables diverse health-care interventions to be
compared, thus enabling broader questions of efficiency to be addressed.
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In this study, the main outcome for the cost-effectiveness analysis was the quality-adjusted life-year
(QALY), assessed using the EQ-5D. The EQ-5D questionnaire is a standardised generic instrument for
measuring health-related quality of life (HRQoL).20 The EQ-5D consists of five health dimensions: mobility,
self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has three levels of
severity (no problems, moderate problems and severe problems) that generate 245 unique health states
into which a patient can be classified. The EQ-5D also provides a single preference weight (also described
as a utility or value) for each health state. These can be used as quality-adjustment weights to turn a
profile of health states over time into QALYs. The EQ-5D has been validated in UK populations and has
been used to measure HRQoL in patients with depression in primary care.26
Resource use and cost data
Information relating to participants’ resource utilisation was obtained via patient self-report using an
adapted version of the CSRI.27 The CSRI was administered at baseline and at each follow-up. Participants
were asked about their use of services in the previous 6 months (including inpatient and outpatient
hospital services, community-based day services, and primary and community care contacts); and whether
or not they had incurred any additional costs associated with their depression (e.g. medication or drug
costs, child-care costs, travel costs). Participants were also asked to record their use of any medication to
help with their depression, including medication name, dose and duration taken.
Unit costs were obtained from routinely published national literature sources, namely the British National
Formulary,28 the Personal Social Services Research Unit’s Unit Costs of Health and Social Care29 and the
NHS reference costs.30 All unit costs were adjusted to 2012/13 prices using the relevant price indices.
Appendix 1 provides sources and details of the unit costs.
The costs of delivering each intervention were limited to those associated with delivering telephone
support, as MoodGYM is a free-to-use software package. The cost of telephone support calls was
estimated based on mean duration and mean number of support calls recorded as part of the study,
and assuming the support was provided by a clinical support worker (band 2). It was assumed, after
consultation with our clinical advisers, that a clinical support worker or a professional in the same pay band
would provide this service in the NHS, if the intervention was to be rolled out.
The unit costs estimates were then combined with the resource utilisation data to obtain a net cost per
patient over the entire follow-up period for the trial. As costs were estimated over a 12-month period, no
discounting was applied.
Economic analysis: statistical methods
Overview
A within-trial economic analysis was conducted to evaluate the cost-effectiveness of telephone-facilitated
cCBT (MoodGYM) and minimally supported cCBT. Costs and health benefits expressed in QALYs were
estimated over the 1-year follow-up. The analysis was conducted on an intention-to-treat basis from the
perspective of the UK NHS and Personal Social Services. All analyses were undertaken in Stata® 12.0
(StataCorp, College Station, TX, USA).
Resource use and costs
Descriptive statistics (mean, SD, median and interquartile range) are reported for resource use and costs.
The descriptive statistics for resource use presented are based on the available case data set as multiple
imputation was only performed for total costs as opposed to individual resource use items. Multiple
imputation by chained equations31 was performed for a total of 10 imputations, and costs were imputed at
every follow-up time point (baseline, 4 and 12 months) for each resource use category. The independent
variables specified in the imputation were baseline EQ-5D score, baseline costs, age, sex, anxiety level at
baseline, depression level at baseline and depression duration at baseline. The descriptive statistics for
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resource use and costs are also reported using unadjusted estimates. Differences in mean costs (and 95% CI)
between the groups were subsequently adjusted for baseline costs and additional participant covariates
using regression analysis (see Cost-effectiveness analysis).
Health-related quality of life
Health-related quality of life was assessed using responses to the EQ-5D questionnaire applied at baseline
and at 4 and 12 months. Missing EQ-5D scores were imputed by multiple imputation by chained equations
alongside costs at the same follow-up time points (baseline, 4 months and 12 months) and specifying the
same independent variables. The EQ-5D scores were used to estimate patient-specific QALYs using the
area under the curve method32 and descriptive statistics were reported. Differences in QALYs (and 95% CI)
between the groups were adjusted for additional participant covariates using regression analysis
(see Cost-effectiveness analysis).
Cost-effectiveness analysis
Incremental estimates of total costs and QALYs were obtained through regression methods, adjusting for
the following baseline characteristics: age, anxiety level, baseline depression severity, depression duration
and sex. The costs and QALY estimates were also adjusted for baseline costs and baseline EQ-5D
scores, respectively.
Incremental QALYs were estimated using ordinary least squares (OLS) regression, as this method has been
recommended for the estimation of QALYs in economic evaluation.33 The regression model applied for the
incremental analysis of costs in the base case was a generalised linear model.34 This type of model was
preferred to an OLS model, as cost data tend to be heavily skewed and follow a non-normal distribution,
which leads to violations of the OLS assumptions. For the analysis of costs, a gamma family distribution
was selected. Selection of the family distribution was based on the modified Park’s test35 performed on
each imputed data set and complete case data set. An identity link function was selected, thus assuming
an additive effect of covariates on costs.
Cost-effectiveness was assessed by comparing the incremental costs and QALYs using standard decision
rules.36 An intervention that generates greater mean QALYs and lower mean costs can be considered
dominant and, therefore, a cost-effective use of resources when compared with the alternative.
When no dominance arises (i.e. one intervention is more costly and more effective than the other), the
interventions can be compared by calculating the ratio between incremental costs and QALYs to establish
the incremental cost-effectiveness ratio (ICER). When the ICER between two interventions is below the
cost-effectiveness threshold that represents the rate at which health-care activities in the NHS (assumed to
be cost-effective) generate health at the margin, then the more costly and more effective intervention is
considered cost-effective. The cost-effectiveness of the interventions was assessed by comparing ICERs
against a cost-effectiveness interval ranging from £20,000 to £30,000 per QALY, in line with NICE
cost-effectiveness thresholds for the UK.37
Uncertainty surrounding the decision was assessed using a probabilistic sensitivity analysis and presented
through cost-effectiveness acceptability curves that graphically represent the probability of an intervention
being cost-effective across a range of cost-effectiveness thresholds. The analysis was performed by
simulating random draws of incremental mean costs and QALYs (n= 1000) from a multivariate normal
distribution and estimating the proportion of those draws that corresponded to a cost-effective use of
resources at cost-effectiveness threshold values ranging from £0 to £60,000 per additional QALY.
In order to plot the cost-effectiveness acceptability curve, the variance–covariance matrices from the
costs and QALYs regressions were extracted and the corresponding Cholesky decompositions calculated
to parameterise multivariate normal distributions.38 This approach is commonly used to ensure that
parameters taken from a regression framework are appropriately correlated and not treated as
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independent when the probabilistic sensitivity analysis is performed (and cost-effectiveness acceptability
curves are plotted), but it has the disadvantage of imposing normality on the sampling distribution.
Base-case and sensitivity analysis
The base-case cost-effectiveness analysis was based on a comparison of all participants receiving minimally
supported cCBT (n= 187) with telephone-facilitated cCBT (n= 182), and conducted on the multiple
imputed data sets. In the base-case analysis, all categories of health-care costs were included, and QALYs
estimated from EQ-5D scores were considered.
A separate sensitivity analysis undertaken, which excluded all non-mental health-related hospital costs
so as to assess the robustness of base-case results to alternative assumptions in terms of costs,
was also considered.
Patient and public participation
Contributors with experience of depression were involved in the design of the trial and the writing of
the protocol, and the chief executive of a user-led organisation was a collaborator and coapplicant.
Two people with depression read the consent forms and questionnaires and commented on the
experience of completing them. All research documentation was designed with patient and public input
and the trial oversight committees included members with experience of mental health problems.
METHODS
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Chapter 3 Protocol changes
Protocol change 1: additional baseline questionnaires
Following the emergence of preliminary findings from the REEACT trial, measures to help identify possible
psychosocial mechanisms that affect participants’ capacity or willingness to engage with cCBT were
approved and added to the baseline CRF. They were to measure:
l need for affect, a measure of the need for emotionally stimulating experiences, which may underlie a
preference for more emotionally engaging material or interaction23
l self-efficacy, a measure of the patient’s confidence that they can overcome typical difficulties to
completing cCBT, which may underlie differences in motivation and ability to persist with
the programme.24
Protocol change 2: baseline client report form
On 29 June 2011, the Research Ethics Committee approved the addition of questions about participants’
current use of antidepressant medication. Following modification of the CRFs, participants were asked the
following additional questions at baseline:
If you are currently taking any medication to help with your depression please give details:
(please include both prescription medicine and any you have bought yourself)
Name of medication . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Dose . . . . . . . . . . . . . . . . . . . . . . .
Name of medication . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Dose . . . . . . . . . . . . . . . . . . . . . . .
How long have you been taking the medicine(s)? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Protocol change 3: extension to the study date and sample size
In December 2012, the Research Ethics Committee approval was given to increase the trial sample size to
350 (175 participants per arm) to allow the detection of a smaller difference of 0.30 with 80% power at a
level of significance of 0.05 (one sided) accounting for loss to follow-up of 20%.
Protocol change 4: primary care depression cohort
In general, studies of depression in primary care can follow the progress of participants for only a short
time and little is known about the effectiveness of treatments in the longer term. Research Ethics
Committee approval was granted on 14 November 2012 to invite participants to continue in the study for
a further 9 years answering questions about their mood and their general health. This extra follow-up
period is not funded as part of the REEACT-2 trial and is not reported here.
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Chapter 4 Clinical effectiveness results
Randomisation and centre details
Four main UK sites were responsible for recruiting to the trial: the Universities of Manchester, Bristol,
Sheffield and York. Table 2 shows the number of participants recruited to each arm by each site.
A total of 369 participants were randomised to the two-armed comparison of minimally supported cCBT
with telephone-facilitated cCBT (n= 182 and n= 187, respectively). The first participant was randomised
on 24 June 2011 and the last on 25 April 2013.
The rate of recruitment is shown in Figure 2. The rate had to be slowed after 3 months of rapid
recruitment to accommodate the TSW workload. The flow of participants through the trial can be seen in
the Consolidated Standards of Reporting Trials (CONSORT) flow chart (Figure 3).
TABLE 2 Participant recruitment by site and allocation
Site Recruited (n)
Trial arm
Minimally supported cCBT (n) Telephone-facilitated cCBT (n)
Bristol 154 70 84
York 124 65 59
Manchester 44 16 28
Sheffield 47 31 16
Total 369 182 187
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FIGURE 2 Cumulative recruitment graph for the REEACT-2 trial.
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Baseline data
Participant characteristics
Baseline demographic characteristics are summarised in Tables 3–7. Continuous variables are presented as
mean, SD, median and range. Categorical variables (e.g. sex) are presented as number and percentage.
The number analysed and the numbers of any missing values are presented.
Returned consent to contact
(n = 602)
Excluded
(n = 233)
• Ineligible, n = 151
• Declined to participate, n = 52
• Unable to be contacted, n = 30
Randomised
(n = 369)
Telephone-facilitated cCBT
(n = 187)
• Did not return questionnaire, n = 36
• Withdrawn from study, n = 6
• Withdrawn from follow-up, n = 4
4-month follow-up
[n = 141 (75.4%)]
• Did not return questionnaire, n = 33
• Withdrawn from study, n = 6
• Withdrawn from follow-up, n = 6
12-month follow-up
[n = 142 (75.9%)]
Minimally supported cCBT
(n = 182)
• Did not return questionnaire, n = 42
• Withdrawn from study, n = 5
• Withdrawn from follow-up, n = 7
4-month follow-up
[n = 128 (70.3%)]
• Did not return questionnaire, n = 36
• Withdrawn from study, n = 5
• Withdrawn from follow-up, n = 9
12-month follow-up
[n = 132 (72.5%)]
FIGURE 3 The CONSORT flow diagram.
TABLE 3 Participant characteristics: age and sex
Participant
Trail arm
Total (n= 369)Minimally supported cCBT (n= 182) Telephone-facilitated cCBT (n= 187)
Sex, n (%)
Male 69 (37.9) 62 (33.2) 131 (35.5)
Female 113 (62.1) 125 (66.8) 238 (64.5)
Patient age (years)
Mean (SD) 40.3 (13.7) 41.0 (13.8) 40.6 (13.8)
Median (range) 40.6 (18.5–74.3) 40.5 (18.2–77.1) 40.6 (18.2–77.1)
Missing 0 0 0
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TABLE 4 Ethnicity
Ethnicity
Trial arm
Total (N= 369),
n (%)
Minimally supported cCBT
(N= 182), n (%)
Telephone-facilitated cCBT
(N= 187), n (%)
White British 173 (95.1) 174 (93.0) 347 (94.0)
Chinese 1 (0.5) 0 (0.0) 1 (0.3)
Other 1 (0.5) 3 (1.6) 4 (1.1)
White Irish 2 (1.1) 0 (0.0) 2 (0.5)
Other white 2 (1.1) 3 (1.6) 5 (1.4)
Mixed – white and black Caribbean 0 (0.0) 2 (1.1) 2 (0.5)
Mixed – white and black African 0 (0.0) 1 (0.5) 1 (0.3)
Mixed – white and Asian 0 (0.0) 1 (0.5) 1 (0.3)
Other mixed 3 (1.6) 0 (0.0) 3 (0.8)
Asian or Asian British – Indian 0 (0.0) 2 (1.1) 2 (0.5)
Asian or Asian British – Pakistani 0 (0.0) 1 (0.5) 1 (0.3)
TABLE 5 Education
Highest qualification
Trial arm
Total (N= 369),
n (%)
Minimally supported cCBT
(N= 182), n (%)
Telephone-facilitated cCBT
(N= 187), n (%)
Question not answered 5 1 6
GCSE/O-level 28 (15.8) 31 (16.7) 59 (16.3)
GCE A-/AS-level or Scottish Higher 23 (13.0) 28 (15.1) 51 (14.0)
NVQ/SVQ levels 1–3 22 (12.4) 24 (12.9) 46 (12.7)
GNVQ (Advanced) 1 (0.6) 6 (3.2) 7 (1.9)
BTEC Certificate 1 (0.6) 2 (1.1) 3 (0.8)
BTEC Diploma 7 (4.0) 3 (1.6) 10 (2.8)
National Certificate or Diploma
(ONC/OND)
10 (5.6) 20 (10.8) 30 (8.3)
Qualified Teacher Status 4 (2.3) 3 (1.6) 7 (1.9)
Higher Education Diploma 6 (3.4) 9 (4.8) 15 (4.1)
Degree (first/ordinary) 33 (18.6) 28 (15.1) 61 (16.8)
Post-graduate certificate 6 (3.4) 5 (2.7) 11 (3.0)
Post-graduate diploma 2 (1.1) 2 (1.1) 4 (1.1)
Master’s degree 10 (5.6) 8 (4.3) 18 (5.0)
PhD 1 (0.6) 2 (1.1) 3 (0.8)
Do not know/no response 17 (9.6) 10 (5.4) 27 (7.4)
Other 6 (3.4) 5 (2.7) 11 (3.0)
A-level, Advanced level; AS-level, Advanced Subsidiary level; BTEC, Business and Technology Education Council;
GCE, General Certificate of Education; GCSE, General Certificate of Secondary Education; GNVQ, General National
Vocational Qualification; NVQ, National Vocational Qualification; O-Level, Ordinary level; ONC, Ordinary National
Certificate; OND, Ordinary National Diploma; PhD, Doctor of Philosophy; SVQ, Scottish Vocational Qualification.
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TABLE 6 Employment details
Employment status
Trial arm
Total (N= 369),
n (%)
Minimally supported cCBT
(N= 182), n (%)
Telephone-facilitated cCBT
(N= 187), n (%)
Baseline employment
Employed part-time 19 (10.4) 33 (17.7) 52 (14.1)
Other 2 (1.1) 1 (0.5) 3 (0.8)
Employed full-time 76 (41.8) 71 (38.2) 147 (39.9)
Self-employed 11 (6.0) 14 (7.5) 25 (6.8)
Retired 11 (6.0) 13 (7.0) 24 (6.5)
Looking after family or home 8 (4.4) 8 (4.3) 16 (4.3)
Not employed but seeking work 15 (8.2) 9 (4.8) 24 (6.5)
Not employed but not seeking work
because of ill health
16 (8.8) 20 (10.8) 36 (9.8)
Not employed but not seeking work
for other reasons
1 (0.5) 2 (1.1) 3 (0.8)
Full-time student 23 (12.6) 15 (8.1) 38 (10.3)
If employed or self-employed, off sick because of depression?
Yes 26 (22.2) 31 (24.8) 57 (23.6)
No 90 (76.9) 94 (75.2) 184 (76.0)
Missing 1 (0.9) 0 (0.0) 1 (0.4)
If unemployed, for how long?
< 3 months 3 (7.7) 5 (10.9) 8 (9.4)
4–12 months 10 (25.6) 9 (19.6) 19 (22.4)
1–2 years 9 (23.1) 5 (10.9) 14 (16.5)
2–5 years 6 (15.4) 7 (15.2) 13 (15.3)
> 5 years 7 (17.9) 10 (21.7) 17 (20.0)
No response 4 (10.3) 10 (21.7) 14 (16.5)
Most recent job
Question not answered 10 5 15
Foreman/supervisor 18 (10.5) 16 (8.8) 34 (9.6)
Manager 33 (19.2) 33 (18.1) 66 (18.6)
Self-employed with employees 5 (2.9) 5 (2.7) 10 (2.8)
Self-employed without employees 8 (4.7) 15 (8.2) 23 (6.5)
Other employee 103 (59.9) 109 (59.9) 212 (59.9)
Never been in paid employment 5 (2.9) 4 (2.2) 9 (2.5)
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The two groups were well balanced at baseline for sex, age, ethnicity and education. The mean age of
participants was 40.6 years (SD 13.8 years). The study population was mostly white British (94%) and
64.5% were female.
The minimally supported cCBT and telephone-facilitated cCBT groups were balanced at baseline for
employment. The majority (61.5%) of participants were employed, and, of these, 23.6% were off work
with depression at the time of their baseline assessment.
TABLE 7 Family details
Family details
Trial arm
Total (N= 369),
n (%)
Minimally supported cCBT
(N= 182), n (%)
Telephone-facilitated cCBT
(N= 187), n (%)
Baseline marriage/family status
Married 68 (37.4) 68 (36.6) 136 (37.0)
Living with a partner 21 (11.5) 36 (19.4) 57 (15.5)
Divorced/separated 24 (13.2) 31 (16.7) 55 (14.9)
Widowed 5 (2.7) 4 (2.2) 9 (2.4)
Single (never married) 63 (34.6) 45 (24.2) 108 (29.3)
Other 1 (0.5) 2 (1.1) 3 (0.8)
If married, does your spouse live with you?
Yes 69 (88.5) 71 (88.8) 140 (88.6)
No 4 (5.1) 2 (2.5) 6 (3.8)
Missing 5 (6.4) 7 (8.8) 12 (7.6)
Do you have other people living with you?
Question not answered 1 1 2
Yes 120 (66.3) 116 (62.4) 236 (64.3)
No 60 (33.1) 70 (37.6) 130 (35.4)
If yes, how many?
1 44 (36.4) 48 (40.0) 92 (38.2)
2 44 (36.4) 32 (26.7) 76 (31.5)
3 18 (14.9) 27 (22.5) 45 (18.7)
4 9 (7.4) 7 (5.8) 16 (6.6)
5 3 (2.5) 1 (0.8) 4 (1.7)
6 0 (0.0) 1 (0.8) 1 (0.4)
≥ 7 2 (1.7) 1 (0.8) 3 (1.2)
Do not know/no response 1 (0.8) 3 (2.5) 4 (1.7)
How many are < 18 years?
0 60 (50.0) 56 (47.1) 116 (48.5)
1 25 (20.8) 30 (25.2) 55 (23.0)
2 23 (19.2) 19 (16.0) 42 (17.6)
3 6 (5.0) 12 (10.1) 18 (7.5)
4 3 (2.5) 1 (0.8) 4 (1.7)
≥ 7 1 (0.8) 0 (0.0) 1 (0.4)
Do not know/no response 2 (1.7) 1 (0.8) 3 (1.3)
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The two groups were balanced at baseline regarding marriage and family status.
Baseline clinical data
The two groups had an imbalance at baseline in the proportion of participants describing themselves as
chronically depressed (11% minimally supported cCBT vs. 5.9% telephone-facilitated cCBT), but the
numbers are very small.
As can be seen in Table 8, the majority of participants (70.7%) had sought help for previous episodes of
depression and 84.5% of these had previously been prescribed antidepressant medication (60.4% of
the trial sample), and 38.8% of participants reported taking antidepressant medication at baseline.
Randomisation resulted in the groups being well balanced for all these variables.
TABLE 8 Previous episodes of depression
Episodes of depression
Trial arm
Total (N= 369),
n (%)
Minimally supported cCBT
(N= 182), n (%)
Telephone-facilitated cCBT
(N= 187), n (%)
Previous episodes of depression when help was sought?
Yes 127 (69.8) 134 (71.7) 261 (70.7)
No 53 (29.1) 52 (27.8) 105 (28.5)
Do not know 2 (1.1) 1 (0.5) 3 (0.8)
If yes, how many episodes of treated depression?
1 36 (28.3) 46 (34.1) 82 (31.3)
2 25 (19.7) 36 (26.7) 61 (23.3)
3 20 (15.7) 9 (6.7) 29 (11.1)
4 12 (9.4) 7 (5.2) 19 (7.3)
≥ 5 20 (15.7) 29 (21.5) 49 (18.7)
Chronically depressed 14 (11.0) 8 (5.9) 22 (8.4)
If yes, prescribed antidepressants for a previous episode?
Yes 109 (85.2) 114 (83.8) 223 (84.5)
No 19 (14.8) 19 (14.0) 38 (14.4)
Do not know 0 (0.0) 3 (2.2) 3 (1.1)
Currently taking medication for depression?
Yes 71 (39.0) 72 (38.5) 143 (38.8)
No 111 (61.0) 115 (61.5) 226 (61.2)
Seen anyone other than your GP? 94 (74.0) 96 (71.1) 190 (72.5)
Psychiatrist 26 (14.4) 25 (13.4) 51 (13.9)
Psychologist 15 (8.3) 16 (8.6) 31 (8.5)
Counsellor 65 (35.7) 66 (35.3) 131 (35.5)
Community psychiatric nurse 10 (5.6) 18 (9.7) 28 (7.7)
Social worker 3 (1.7) 3 (1.6) 6 (1.6)
Citizens advice bureau 0 0 0
Other statutory/voluntary agency 3 (1.7) 10 (5.4) 13 (3.6)
Other 12 (6.7) 10 (5.4) 22 (6.0)
Do not know 0 (0.0) 1 (0.5) 1 (0.3)
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Primary outcome
Patient Health Questionnaire-9 descriptive summaries
At the 4-month follow-up, a PHQ-9 score was missing for 27% of participants who did not return the
4-month questionnaire, 25% in the telephone-facilitated cCBT group and 30% in the minimally supported
cCBT group. These numbers were slightly lower at month 12, 24% in the telephone-facilitated cCBT group
and 27% in the minimally supported cCBT group, as a small number of participants completed a 12-month
but not a 4-month questionnaire. Scores are summarised in Table 9.
Participants in the telephone-facilitated cCBT group had lower mean PHQ-9 scores at month 4 (indicating
a reduction in depression) with a between-group difference of 1.9 at month 4 and 1 at month 12.
Primary analyses: depressed/not depressed (Patient Health Questionnaire-9)
at month 4
Primary analysis results are shown in Table 10. After 4 months, 66 (50.30%) of the 128 participants in the
minimally supported cCBT group and 51 (36.2%) of the 141 in the telephone-facilitated cCBT group had a
PHQ-9 score of ≥ 10.
TABLE 9 Patient Health Questionnaire-9 scores at each time point
PHQ-9
Time point
Baseline Month 4 Month 12
Minimally
supported
cCBT (n= 182)
Telephone-
facilitated
cCBT (n= 187)
Minimally
supported
cCBT (n= 128)
Telephone-
facilitated
cCBT (n= 141)
Minimally
supported
cCBT (n= 132)
Telephone-
facilitated
cCBT (n= 142)
PHQ-9 score
Mean (SD) 16.4 (4.1) 16.8 (3.9 10.4 (6.4) 8.5 (6.3) 9.2 (6.2) 8.2 (6.4)
Median 16 17 10 7 9 7
Range 10–25 10–26 0–27 0–24 0–25 0–27
PHQ-9 dichotomised
Depressed,
n (%)
182 (100) 187 (100) 66 (51.6) 51 (36.2) 57 (43.2) 46 (32.4)
Not depressed,
n (%)
0 0 62 (48.4) 90 (63.8) 75 (56.8) 96 (67.6)
Missing, n (%) 0 0 54 (30) 46 (25) 50 (27) 45 (24)
TABLE 10 Primary analysis of depression at 4 months as a discrete outcome
Effect OR 95% CI p-value
Telephone-facilitated cCBT vs. minimally supported cCBT 2.050 1.227 to 3.424 0.0061
Male vs. female 0.957 0.559 to 1.638 0.8713
Baseline PHQ-9 score 0.882 0.819 to 0.951 0.0011
Baseline GAD-7 score 0.964 0.903 to 1.029 0.2654
Age (years) 1.012 0.994 to 1.031 0.1981
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As a sensitivity analysis, an alternative scenario was also considered that assumed all participants who did
not supply follow-up data remained depressed.
Both primary and sensitivity analyses of depression as a discrete outcome show a significant difference
between the groups with respect to the odds of not being depressed at 4 months. For the primary analysis
the OR was 2.05 (95% CI 1.23 to 3.24; p= 0.006), indicating that adding telephone support to cCBT
doubled the odds of not being depressed. The baseline PHQ-9 score was also a significant predictor,
indicating that a higher baseline score was related to a reduced chance of not being depressed. Table 11
shows the results of the sensitivity analysis, which included all participants and assumed that those with
missing data were still depressed. The conclusion regarding the addition of telephone support was the
same. In this analysis, age and baseline GAD-7 score also had statistically significant relationships with the
odds of not being depressed. Older participants were more likely to not be depressed at month 4, whereas
those participants with higher baseline depression and anxiety were less likely not to be depressed.
The missing data were explored using univariate logistic regression models to compare baseline factors
between those with and those missing a month-4 PHQ-9 score. There was no relationship between
missing assessments and treatment (p= 0.274), baseline PHQ-9 score (p= 0.898), sex (p= 0.272) or taking
current medication for depression (p= 0.134). However, age (OR 1.03, 95% CI 1.01 to 1.05; p= 0.002)
and baseline GAD-7 score (OR 0.94, 95% CI 0.89 to 0.99; p= 0.023) were both significantly associated
with the odds of missing a month-4 assessment. This indicates that older participants were more likely
to have a missing assessment, and those with higher anxiety at baseline were less likely to have a
missing assessment.
Secondary analyses: depressed/not depressed (Patient Health Questionnaire-9)
at month 12
Tables 12 and 13 show the results of modelling the odds of being depressed or not depressed at month 12,
with a graphical representation in Figure 4. Again the analysis was carried out with all available data
and then with the assumption that participants whose data were missing remained depressed as a
sensitivity analysis.
TABLE 11 Sensitivity analysis
Effect OR 95% CI p-value
Telephone-facilitated cCBT vs. minimally supported cCBT 1.945 1.253 to 3.019 0.0030
Male vs. female 0.784 0.496 to 1.240 0.2977
Baseline PHQ-9 score 0.925 0.869 to 0.984 0.0137
Baseline GAD-7 score 0.938 0.887 to 0.991 0.0232
Age (years) 1.020 1.004 to 1.037 0.0132
TABLE 12 Depression at 12 months as a discrete outcome
Effect OR 95% CI p-value
Telephone-facilitated cCBT vs. minimally supported cCBT 1.626 0.977 to 2.705 0.0615
Male vs. female 1.111 0.651 to 1.897 0.6996
Baseline PHQ-9 score 0.898 0.833 to 0.967 0.0046
Baseline GAD-7 score 0.965 0.904 to 1.031 0.2892
Age (years) 1.004 0.986 to 1.023 0.6764
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These results show that telephone-facilitated cCBT was better than minimally supported cCBT for
increasing the chances of no longer being depressed after 12 months, but this was not statistically
significant (OR 1.63, 95% CI 0.98 to 2.71; p= 0.06). However, in the sensitivity analysis, assuming
participants with a missing PHQ-9 score were still depressed, telephone-facilitated cCBT was significantly
better (OR 1.61, 95% CI 1.05 to 2.47; p= 0.03).
The OR was 1.61 (95% CI 1.05 to 2.47; p= 0.028) for the main analysis and 1.63 (95% CI 0.98 to 2.71;
p= 0.062) for the sensitivity analysis, indicating that adding telephone support to cCBT increased the odds
of no longer being depressed by approximately 60%. The baseline PHQ-9 score was also a significant
predictor, indicating that a higher baseline score was related to a reduced chance of not being depressed.
Secondary analyses: repeated measures analysis of Patient Health
Questionnaire-9 score
The mixed repeated measures model is reported in Tables 14 and 15. These results show a statistically
significant overall effect of treatment (p= 0.025), indicating that over both follow-up assessments the
addition of telephone support to cCBT reduced the PHQ-9 score by approximately –1.41 (95% CI –2.63 to
–0.17). Over both groups there was also a statistically significant reduction over time (p= 0.025), indicating a
general decrease in score over time. The baseline PHQ-9 score was a significant predictor of follow-up PHQ-9
score (p< 0.001) but there was no evidence of any relationship with age, sex or baseline GAD-7 score.
TABLE 13 Sensitivity analysis of depression at 12 months as a discrete outcome, assuming that those with missing
data were still depressed
Effect OR 95% CI p-value
Telephone-facilitated cCBT vs. minimally supported cCBT 1.613 1.051 to 2.474 0.0286
Male vs. female 0.979 0.627 to 1.528 0.9249
Baseline PHQ-9 score 0.930 0.875 to 0.987 0.0177
Baseline GAD-7 score 0.941 0.891 to 0.994 0.0290
Age (years) 1.018 1.002 to 1.034 0.0263
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FIGURE 4 Mean and 95% CI of PHQ-9 score at each assessment.
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The PHQ-9 score for telephone-facilitated cCBT was significantly lower than minimally supported cCBT
after 4 months (mean between-group difference –1.89, 95% CI –3.30 to –0.49; Cohen’s d= 0.324;
p= 0.009), but there was no evidence of any difference after 12 months.
Generalised Anxiety Disorder Scale-7 items
The GAD-7 questionnaire was measured at baseline and at 4 and 12 months.
Secondary analyses: Generalised Anxiety Disorder Scale-7 items
The GAD-7 questionnaire was administered to assess self-reported anxiety at baseline and at 4 and
12 months. The mean score decreased in both groups during both follow-up periods.
Table 16 and Figure 5 show the mean GAD-7 scores for each group for the period for the trial. The scores
in each group decreased over both time periods.
Results are from a mixed model with repeated measures within participants to allow for within-participant
correlation. An unstructured covariance matrix was used. The model analysed GAD-7 scores at months 4
and 12, and adjusted for age, sex, baseline PHQ-9 score, baseline GAD-7 score, time (as a categorical
variable) and treatment.
Cohen’s d effect size was calculated as an estimate of mean difference/overall SD.
TABLE 14 Analysis of PHQ-9 score at each time point
Effect Estimate 95% CI F-value p-value
Baseline PHQ-9 score 0.4813 0.3025 to 0.6600 28.07 < 0.0001
Baseline GAD-7 score 0.1301 –0.02763 to 0.2878 2.64 0.1056
Age (years) –0.0183 –0.0622 to 0.0256 0.68 0.4119
Sex 0.4899 –0.8039 to 1.7836 0.75 0.4567
Time Overall effect 5.08 0.0250
Treatment Overall effect 5.05 0.0253
Treatment × time interaction Overall effect 1.94 0.1645
TABLE 15 Mean differences in PHQ-9 score
Effect Cohen’s d effect size Estimate 95% CI t-value p-value
Telephone-facilitated cCBT vs.
minimally supported cCBT
(month 4)
0.324 –1.8923 –3.2969 to –0.4877 2.65 0.0085
Telephone-facilitated cCBT vs.
minimally supported cCBT
(month 12)
0.155 –0.9192 –2.3341 to 0.4957 1.28 0.2020
Telephone-facilitated cCBT vs.
minimally supported cCBT
(over all assessments)
–1.4057 –2.6336 to –0.1748 2.25 0.0253
Month 4 vs. month 12
(over all treatments)
0.7866 0.0995 to 1.4737 2.25 0.0250
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The results in Tables 17 and 18 show a statistically significant overall effect of treatment (p= 0.037),
indicating that over the whole follow-up period the addition of telephone support to cCBT reduced the
GAD-7 score by approximately –1.18 (95% CI –2.28 to –0.07). However, when comparing the treatments
separately at month 4 and month 12, there was no statistically significant difference between them at
either assessment. Baseline GAD-7 and PHQ-9 scores were significant predictors of follow-up GAD-7 score.
TABLE 16 Generalised Anxiety Disorder Scale-7 items score
Time point
Trial arm
Total (n= 369)Minimally supported cCBT (n= 182) Telephone-facilitated cCBT (n= 187)
Baseline
Mean (SD) 14.1 (4.4) 14.5 (4.4) 14.3 (4.4)
Median (range) 14.0 (4.0–21.0) 15.0 (3.0–21.0) 15.0 (3.0–21.0)
Missing 0 0 0
Month 4
Mean (SD) 8.6 (5.4) 7.5 (6.1) 8.1 (5.8)
Median (range) 8.0 (0.0–21.0) 6.0 (0.0–21.0) 7.0 (0.0–21.0)
Missing 65 59 124
Month 12
Mean (SD 8.2 (5.6) 7.0 (5.7) 7.6 (5.7)
Median (range) 7.0 (0.0–21.0) 5.0 (0.0–21.0) 6.0 (0.0–21.0)
Missing 59 56 115
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FIGURE 5 Mean and 95% CI of GAD-7 scores at each assessment.
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Patient Health Questionnaire-15
The PHQ-15 was administered to assess somatoform symptoms at baseline and at 4 and 12 months,
and descriptive statistics are presented in Table 19 and Figure 6.
Results are from a mixed model with repeated measures within participants to allow for within-participant
correlation. An unstructured covariance matrix was used. The model analysed PHQ-15 scores at months 4
and 12, and adjusted for age, sex, baseline PHQ-15 score, baseline GAD-7 score, time (as a categorical
variable) and treatment.
Cohen’s d effect size was calculated as an estimate of mean difference/overall SD.
TABLE 17 Repeated measures analysis of GAD-7 scores
Effect Estimate 95% CI F-value p-value
Baseline PHQ-9 score 0.1992 0.0388 to 0.3596 5.98 0.0151
Baseline GAD-7 score 0.4338 0.2917 to 0.5759 36.12 < 0.0001
Age (years) –0.0358 –0.0750 to 0.0034 3.24 0.0730
Sex 0.5970 –0.5812 to 1.7752 0.99 0.3194
Time Overall effect 3.34 0.0690
Treatment Overall effect 4.42 0.0365
Treatment × time interaction Overall effect 0.02 0.8806
TABLE 18 Mean differences in GAD-7 score
Effect Cohen’s d effect size Estimate 95% CI t-value p-value
Telephone-facilitated cCBT vs.
minimally supported cCBT
(month 4)
0.236 –1.2291 –2.4374 to 0.1425 1.85 0.0659
Telephone-facilitated cCBT vs.
minimally supported cCBT
(month 12)
0.166 –1.1269 –2.3122 to 0.1676 1.75 0.0819
Telephone-facilitated cCBT vs.
minimally supported cCBT
(over all assessments)
–1.1780 –2.2813 to –0.0747 2.10 0.0365
Month 4 vs. month 12
(over all treatments)
0.6203 –0.0487 to 1.2894 1.83 0.0690
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TABLE 19 Secondary analyses: PHQ-15 score
Time point
Trial arm
Total (n= 369)Minimally supported cCBT (n= 182) Telephone-facilitated cCBT (n= 187)
Baseline
Mean (SD) 11.5 (4.8) 11.9 (5.0) 11.7 (4.9)
Median (range) 11.0 (1.0–28.0) 11.0 (1.0–28.0) 11.0 (1.0–28.0)
Missing 0 0 0
Month 4
Mean (SD) 8.7 (4.7) 8.8 (5.5) 8.7 (5.1)
Median (range) 8.0 (0.0–21.4) 8.0 (0.0–25.0) 8.0 (0.0–25.0)
Missing 66 59 125
Month 12
Mean (SD) 9.0 (5.1) 8.2 (5.0) 8.6 (5.1)
Median (range) 8.0 (0.0–25.0) 7.0 (0.0–20.0) 8.0 (0.0–25.0)
Missing 60 57 117
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FIGURE 6 Mean and 95% CI of PHQ-15 score at each assessment.
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These results (Tables 20 and 21) show a borderline statistically significant overall effect of treatment
(p= 0.051), indicating that over the whole follow-up period the addition of telephone support to cCBT
reduced the PHQ-15 score by approximately –1.11 (95% CI –1.75 to 0.002). When comparing the
treatments separately at month 4 and month 12, there was no statistically significant difference between
them at month 4 but the PHQ-15 score was significantly lower with the addition of telephone facilitation
at month 12 (mean difference –1.24, 95% CI –2.27 to –0.21; p= 0.018).
Baseline PHQ-15 score was the only other significant predictor of follow-up PHQ-15 score (see Table 20).
TABLE 21 Mean differences in PHQ-15 score
Effect Cohen’s d effect size Estimate 95% CI t-value p-value
Telephone-facilitated cCBT
vs. minimally supported cCBT
(month 4)
0.121 –0.5088 –1.5701 to 0.5526 0.94 0.3460
Telephone-facilitated cCBT
vs. minimally supported cCBT
(month 12)
0.300 –1.2410 –2.2692 to –0.2127 2.38 0.0182
Telephone-facilitated cCBT
vs. minimally supported cCBT
(over all assessments)
–1.1099 –1.7521 to 0.0024 1.96 0.0506
Month 4 vs. month 12
(over all treatments)
0.3211 –0.2463 to 0.8884 1.11 0.2661
TABLE 20 Repeated measures analysis of PHQ-15 score
Effect Estimate 95% CI F-value p-value
Baseline GAD-7 score 0.0467 –0.0558 to 0.1491 0.81 0.3704
Baseline PHQ-15 score 0.5800 0.4819 to 0.6780 135.66 < 0.0001
Age (years) 0.0062 –0.0252 to 0.0375 0.15 0.6994
Sex –0.5926 –1.5394 to 0.3542 1.52 0.2189
Time Overall effect 1.24 0.2661
Treatment Overall effect 3.85 0.0506
Treatment × time interaction Overall effect 1.62 0.2050
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European Quality of Life-5 Dimensions
The EQ-5D is summarised descriptively at each time point showing the number and percentage of
participants with each type of response (Tables 22–26).
TABLE 22 European Quality of Life-5 Dimensions mobility at each time point
Time point
Trial arm
Total (N= 369),
n %
Minimally supported cCBT
(N= 182) n %
Telephone-facilitated cCBT
(N= 187) n %
Baseline
I have no problems in walking about 162 (89.5) 151 (80.7) 313 (85.1)
I have some problems in walking about 19 (10.5) 36 (19.3) 55 (14.9)
I am confined to bed 0 (0.0) 0 (0.0) 0 (0.0)
Month 4
I have no problems in walking about 98 (83.8) 103 (80.5) 201 (82.0)
I have some problems in walking about 19 (16.2) 25 (19.5) 44 (18.0)
I am confined to bed 0 (0.0) 0 (0.0) 0 (0.0)
Month 12
I have no problems in walking about 101 (82.1) 108 (82.4) 209 (82.3)
I have some problems in walking about 22 (17.9) 23 (17.6) 45 (17.7)
I am confined to bed 0 (0.0) 0 (0.0) 0 (0.0)
TABLE 23 European Quality of Life-5 Dimensions self-care at each time point
Time point
Trial arm
Total (N= 369),
n %
Minimally supported cCBT
(N= 182) n %
Telephone-facilitated cCBT
(N= 187) n %
Baseline
I have no problems with self-care 171 (94.5) 173 (92.5) 344 (93.5)
I have some problems with self-care 10 (5.5) 14 (7.5) 24 (6.5)
I am unable to wash or dress myself 0 (0.0) 0 (0.0) 0 (0.0)
Month 4
I have no problems with self-care 107 (91.5) 121 (94.5) 228 (93.1)
I have some problems with self-care 10 (8.5) 7 (5.5) 17 (6.9)
I am unable to wash or dress myself 0 (0.0) 0 (0.0) 0 (0.0)
Month 12
I have no problems with self-care 116 (94.3) 123 (93.9) 239 (94.1)
I have some problems with self-care 7 (5.7) 8 (6.1) 15 (5.9)
I am unable to wash or dress myself 0 (0.0) 0 (0.0) 0 (0.0)
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TABLE 24 European Quality of Life-5 Dimensions usual activities at each time point
Time point
Trial arm
Total (N= 369),
n %
Minimally supported cCBT
(N= 182) n %
Telephone-facilitated cCBT
(N= 187) n %
Baseline
I have no problems with performing my
usual activities
84 (46.4) 70 (37.4) 154 (41.8)
I have some problems with performing
my usual activities
89 (49.2) 106 (56.7) 195 (53.0)
I am unable to perform my usual activities 8 (4.4) 11 (5.9) 19 (5.2)
Month 4
I have no problems with performing my
usual activities
68 (58.1) 76 (59.4) 144 (58.8)
I have some problems with performing
my usual activities
46 (39.3) 47 (36.7) 93 (38.0)
I am unable to perform my usual activities 3 (2.6) 5 (3.9) 8 (3.3)
Month 12
I have no problems with performing my
usual activities
78 (63.4) 79 (60.3) 157 (61.8)
I have some problems with performing
my usual activities
43 (35.0) 47 (35.9) 90 (35.4)
I am unable to perform my usual activities 2 (1.6) 5 (3.8) 7 (2.8)
TABLE 25 European Quality of Life-5 Dimensions pain/discomfort at each time point
Time point
Trial arm
Total (N= 369),
n %
Minimally supported cCBT
(N= 182) n %
Telephone-facilitated cCBT
(N= 187) n %
Baseline
I have no pain or discomfort 84 (46.4) 84 (44.9) 168 (45.7)
I have moderate pain or discomfort 87 (48.1) 88 (47.1) 175 (47.6)
I have extreme pain or discomfort 10 (5.5) 15 (8.0) 25 (6.8)
Month 4
I have no pain or discomfort 56 (47.9) 62 (48.4) 118 (48.2)
I have moderate pain or discomfort 57 (48.7) 60 (46.9) 117 (47.8)
I have extreme pain or discomfort 4 (3.4) 6 (4.7) 10 (4.1)
Month 12
I have no pain or discomfort 58 (47.2) 67 (51.1) 125 (49.2)
I have moderate pain or discomfort 60 (48.8) 56 (42.7) 116 (45.7)
I have extreme pain or discomfort 5 (4.1) 8 (6.1) 13 (5.1)
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Computerised cognitive behaviour therapy usage
MoodGYM modules were reported as 25%, 50%, 75% or 100% complete. The percentage of
participants in each intervention group who completed all or part of each module is shown in Table 27.
The telephone-facilitation programme has increased completion rates for each module (Figure 7).
Medication to help with depression use
Participants were asked whether or not they were taking medication to help with depression. This included
over-the-counter and prescribed medication. Their responses are reported in Table 28.
Early participants in the trial were not asked about current medication; data collection started at
participant 1151, so numbers at baseline are smaller. The proportions of participants currently taking
medication for depression were similar between the two groups at baseline.
Adverse events
There were a total of 10 serious adverse events (Table 29), none of which was thought to be related to
the trial. All adverse events were reviewed by the Trial Steering Committee and the Data Monitoring and
Ethics Committee.
TABLE 26 European Quality of Life-5 Dimensions anxiety/depression at each time point
Time point
Trial arm
Total (N= 369),
n %
Minimally supported cCBT
(N= 182) n %
Telephone-facilitated cCBT
(N= 187) n %
Baseline
I am not anxious or depressed 17 (9.4) 9 (4.8) 26 (7.1)
I am moderately anxious or depressed 116 (64.1) 131 (70.1) 247 (67.1)
I am extremely anxious or depressed 48 (26.5) 47 (25.1) 95 (25.8)
Month 4
I am not anxious or depressed 27 (22.9) 38 (29.7) 65 (26.4)
I am moderately anxious or depressed 78 (66.1) 74 (57.8) 152 (61.8)
I am extremely anxious or depressed 13 (11.0) 16 (12.5) 29 (11.8)
Month 12
I am not anxious or depressed 35 (28.5) 57 (43.5) 92 (36.2)
I am moderately anxious or depressed 72 (58.5) 61 (46.6) 133 (52.4)
I am extremely anxious or depressed 16 (13.0) 13 (9.9) 29 (11.4)
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FIGURE 7 MoodGYM usage session by session.
TABLE 28 Self-reported antidepressant medication use
Time point
Trial arm
Total, n (%)Minimally supported cCBT, n (%) Telephone-facilitated cCBT, n (%)
Baseline N= 107 N= 111 N= 218
Yes 71 (66.0) 74 (66.7) 145 (66.5)
No 36 (33.6) 37 (33.3) 73 (33.5)
Month 4 N= 128 N= 141 N= 269
Yes 84 (65.6) 85 (60.3) 169 (62.8)
No 44 (34.4) 56 (39.7) 100 (37.2)
Month 12 N= 132 N= 142 N= 274
Yes 70 (53.0) 68 (47.9) 138 (50.4)
No 62 (47.0) 74 (52.1) 136 (49.6)
TABLE 29 Serious adverse events
Serious adverse events
Trial arm
TotalMinimally supported cCBT Telephone-facilitated cCBT
Number of events 4 6 10
Number unrelated to the trial 4 6 10
Reason for designation
Hospitalisation 1 2 3
Life-threatening 2 1 3
Death 0 1 1
Resulting in disability or incapacity 1 2 3
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Chapter 5 Economic evaluation results
Health-care resource use
Table 30 reports the descriptive statistics of health-care resource use by resource category during the trial
follow-up.
Full resource-use data were available for all participants at baseline, and this decreased during follow-up
to 67% at 4 months and 69% at 12 months, with complete data across the trial period available for
58.1% of participants from minimally supported cCBT (n= 98) and 59.4% from telephone-facilitated
cCBT (n= 111).
TABLE 30 Resource use from baseline to 12 months of follow-up in available case data set
Health care Unit
Trial arm
Minimally supported cCBT (n= 98) Telephone-facilitated cCBT (n= 111)
Mean (SD) Median (IQR) Use (%) Mean (SD) Median (IQR) Use (%)
Community care
GP Visit 7.39 (6.43) 5.33 (10) 98.98 6.67 (4.8) 5.33 (10) 92.2
GP home visit Visit 0.01 (0.67) 0 (0) 1.02 0.02 (0.15) 0 (0) 2.7
Nurse Visit 1.02 (1.52) 0 (1.33) 48.98 1.44 (2.58) 0.67 (2) 52.25
Other primary care Visit 0.39 (1.9) 0 (0) 8.16 2.08 (19.77) 0 (0) 5.41
All day based services Visit 0.41 (2.83) 0 (0) 6.12 0.17 (1.00) 0 (0) 3.6
Counsellor Visit 1.34 (3.56) 0 (0) 23.47 1.16 (3.27) 0 (0.67) 26.13
Psychiatric nurse Visit 0.19 (0.90) 0 (0) 7.14 0.50 (3.39) 0 (0) 6.31
Hospital services
Inpatient
Mental health relateda Bed-days 0 (0) 0 (0) 0.00 0 (0) 0 (0) 0.00
Non-mental health relatedb Bed-days 0.24 (1.44) 0 (0) 6.12 0.52 (2.15) 0 (0) 12.61
Outpatient
Psychiatrist Visit 0.43 (2.36) 0 (0) 7.14 0.03 (0.26) 0 (0) 1.8
Clinical psychology Visit 0.43 (2.36) 0 (0) 7.14 0.03 (0.26) 0 (0) 1.8
Non-mental health relatedc Visit 1.95 (3.67) 0.33 (2) 50 1.59 (4.07) 0 (1.33) 44.14
IQR, interquartile range.
a Mental health-related inpatient services included acute psychiatric care wards, psychiatric rehabilitation wards and
psychiatric intensive care units.
b Non-mental health-related inpatient services included general medical wards and long-stay wards.
c Non-mental health-related outpatient wards included accident and emergency services and any other outpatient
admissions stated.
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General practitioners were visited by nearly all participants throughout the trial (95.08%) but were, on
average, more frequently attended by those in the minimally supported cCBT group (mean 7.39 visits) than
those in the telephone-facilitated cCBT group (mean 6.67 visits). Hospital inpatient services (both mental
health and non-mental health related) were used infrequently across each trial arm for both mental
health- and non-mental health-related services. Outpatient hospital attendance for non-mental health-related
illnesses was common across both minimally supported cCBT (50%) and telephone-facilitated cCBT (44%).
Inpatient mental health-related hospital attendances were low across both groups. Results should be
interpreted cautiously as these are unadjusted estimates from the available case data set.
Costs
Table 31 reports the mean costs from baseline to 12 months by treatment group. Mean total costs for the
12-month follow-up were £1172 for minimally supported cCBT versus £1763 for telephone-facilitated
cCBT. Total costs appeared broadly similar across both trial arms for mental health-related hospital costs,
GP costs, primary care costs and medication costs. However, large disparities were seen in non-mental
health-related hospital costs when average costs for telephone-facilitated cCBT (£1050.53) were high with
large standard errors compared with the average minimally supported cCBT cost (£561.50). These hospital
costs appear to be driven by single participants who had higher costs for ongoing treatments not related
to depression. The resultant total costs for these individuals could be considered as outliers. The adjusted
mean differences and corresponding 95% CIs obtained through regression analysis are reported in
Cost-effectiveness analysis.
TABLE 31 Summary of costs
Cost category
Trial arm
Minimally supported cCBT
(n= 182), mean (SE) (£)
Telephone-facilitated cCBT
(n= 187), mean (SE) (£)
NHS costs
Hospital costs (mental health) 109.08 (39.59) 115.21 (39.39)
Hospital costs (non-mental health) 561.50 (153.88) 1050.53 (383.1)
GP costs 381.58 (40.93) 390.62 (44.00)
Other primary care 111.43 (25.18) 158.08 (39.33)
Medication costs 8.52 (0.79) 7.85 (0.93)
Intervention costs
Telephone support – 41.19
Baseline costs 508.71 (51.59) 796.49 (131.26)
Total costs 1172.12 (186.53) 1763.48 (438.77)
SE, standard error.
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Health-related quality of life
Table 32 summarises the EQ-5D scores at baseline and at each follow-up period, and total QALYs over the
12-month follow-up. On average, patients in the telephone-facilitated cCBT group reported a slightly lower
quality of life than the minimally supported cCBT group at baseline and 4 months, but better quality of life
at 12 months.
Mean QALYs estimated through the EQ-5D over 12 months were 0.70 for minimally supported cCBT and
0.686 for telephone-facilitated cCBT. As with the individual EQ-5D scores, the overall QALY difference
appears small based on the unadjusted means.
Cost-effectiveness analysis
Base-case cost-effectiveness results
Estimates of incremental mean costs and QALYs based on the regression analysis above were used in the
cost-effectiveness analysis. Table 33 presents the fully incremental cost-effectiveness estimates and
probability that each intervention is cost-effective at a threshold of £20,000 and £30,000 per QALY.
Telephone-facilitated cCBT appears less costly (mean cost difference £3.42) and more effective (mean QALY
difference 0.0026) than minimally supported cCBT. At a cost-effectiveness threshold of £20,000 and
£30,000 per QALY, the probability that telephone-facilitated cCBT is a cost-effective intervention is 0.55.
TABLE 32 European Quality of Life-5 Dimensions summary scores and QALY estimates (mean, standard error)
Time point/outcome
Trial arm
Minimally supported cCBT (n= 182) Telephone-facilitated cCBT (n= 187)
Baseline 0.620 (0.020) 0.590 (0.021)
4-month follow-up 0.720 (0.021) 0.699 (0.024)
12-month follow-up 0.710 (0.020) 0.716 (0.023)
QALYs 0.700 (0.016) 0.686 (0.019)
TABLE 33 Cost-effectiveness analysis summary table: base case
Treatment
Incremental
costsa,b
Incremental
QALYsa,c ICER
Probability cost-effective
£20,000 per QALY
Probability cost-effective
£30,000 per QALY
Minimally supported
cCBT
0 0 Dominated 0.45 0.46
Telephone-facilitated
cCBT
–£3.42 0.0026 0.55 0.55
a Comparing telephone-facilitated cCBT with minimally supported cCBT.
b Adjusted for baseline costs, age, anxiety level, baseline depression severity, depression duration and sex.
c Adjusted for baseline EQ-5D score, age, anxiety level, baseline depression severity, depression duration and sex.
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Figure 8 presents the cost-effectiveness acceptability curves for each treatment. The curve indicates the
probability that each intervention is the most cost-effective for a range of maximum amounts that
the NHS may be willing to pay to gain an additional QALY. The curve illustrates that the probability that
telephone-facilitated cCBT is cost-effective initially increases as the amount the NHS is assumed to be
willing to pay for additional health gain rises, becoming fairly stable for higher cost-effectiveness thresholds
(approximately ≥ £15,000 per QALY).
As a sensitivity analysis, an alternative costing scenario was also considered, which included the same cost
categories as the base-case analysis with the exception of all non-mental health-related hospital costs. The
cost-effectiveness results are reported in Table 34 and Figure 9. In contrast to previous analyses, minimally
supported cCBT is no longer dominated by telephone-facilitated cCBT. The ICER for the comparison of
telephone-facilitated cCBT versus minimally supported cCBT is £3596 per QALY. Since this is below the
lower bound of the currently recommended NICE cost-effectiveness threshold (£20,000 per QALY),
minimally supported cCBT remains the cost-effective intervention in this comparison. At a cost-effectiveness
threshold of £20,000 per QALY, the probability that telephone-facilitated cCBT is the cost-effective
intervention is 0.55. As for the base-case, the probability of cost-effectiveness across thresholds becomes
stable at > £15,000 per QALY, with probability of cost-effectiveness for either intervention remaining equal
at £20,000 and £30,000 per QALY.
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FIGURE 8 Cost-effectiveness acceptability curves: base case.
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Summary
The within-trial results of the economic analysis suggest that telephone-facilitated cCBT appeared
cost-effective compared with the minimally supported cCBT. In the base case, telephone-facilitated cCBT
dominated minimally supported cCBT (i.e. lower mean costs and higher QALYs). Although no longer
dominant, telephone-facilitated cCBT remained a cost-effective intervention in the sensitivity analyses
(i.e. was well within conventional thresholds used to determine value for money in the NHS of
£20,000–30,000 per QALY). However, the differences between the groups were relatively minor for
both cost and QALY estimates in each of the separate analyses. Although telephone-facilitated cCBT
consistently appeared the cost-effective treatment in the base-case and sensitivity analyses, the results from
the probabilistic sensitivity analysis revealed high levels of uncertainty.
TABLE 34 Cost-effectiveness analysis summary table: sensitivity analysis excluding non-mental health-related
hospital costs
Treatment
Incremental
costsa,b,c
Incremental
QALYsa,d ICER
Probability cost-effective
£20,000 per QALY
Probability cost-effective
£30,000 per QALY
Minimally supported
cCBT
0 0 – 0.45 0.45
Telephone-facilitated
cCBT
£9.37 0.0026043 £3596.62 0.55 0.55
a Comparing telephone-facilitated cCBT to minimally supported cCBT.
b Adjusted for baseline costs, age, anxiety level, baseline depression severity, depression duration and sex.
c Includes primary care (GP and other), and mental health-related hospital and medication costs.
d Adjusted for baseline EQ-5D score, age, anxiety level, baseline depression severity, depression duration and sex.
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FIGURE 9 Cost-effectiveness acceptability curves: sensitivity analysis excluding non-mental health-related
hospital costs.
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Chapter 6 Discussion
The REEACT-2 trial is, to our knowledge, the first head-to-head comparison of minimally supportedversus telephone-facilitated cCBT in UK primary care. It answers an important question relating to the
level of support required for cCBT in clinical practice in order to ensure uptake of the technology and its
clinical effectiveness. The REEACT-2 trial results build on an earlier Health Technology Assessment
programme-funded trial (REEACT) in which it was found that cCBT was not effective in the form that it
was delivered in routine NHS care (i.e. with minimal professional support).12 The REEACT-2 trial specifically
tests the hypothesis that increasing the level of professional support offered alongside cCBT leads to a
greater level of engagement with the computer technology and in turn leads to improved outcomes.
The need for the REEACT-2 trial was highlighted by the negative results of the REEACT trial and the
emergence of indirect evidence from systematic reviews which showed that meta-analyses of professionally
supported cCBT demonstrated larger effect sizes than minimally supported cCBT.9
Prior to the REEACT and REEACT-2 trials there had been no large-scale pragmatic trials of cCBT products
in UK primary care and the REEACT trials were commissioned following an earlier technology appraisal in
this area that identified the need for trials conducted independently of product developers.6 The cCBT
technology evaluated in the REEACT-2 trial (MoodGYM) was recommended in depression guidelines issued
by NICE at the time of design of the REEACT-2 trial, and MoodGYM remains a NICE-endorsed treatment
at the time of publication of this trial.39
The REEACT-2 trial was unusual in comparison with earlier trial-based evaluations in that it included an
extended follow-up to 12 months. Outcomes were measured across a broad range of domains, including
psychological well-being and quality-of-life/health state utility. Important aspects of service utilisation were
also recorded, and the trial included a concurrent economic evaluation.
The main findings of the REEACT-2 study will now be discussed in relation to (1) trial-based estimates
of the clinical effectiveness of telephone facilitation of cCBT and (2) trial-based estimates of
cost-effectiveness.
Trial-based estimates of the clinical effectiveness of
telephone-facilitated computer-delivered cognitive
behaviour therapy
The REEACT-2 trial found that when telephone facilitation was added to cCBT there were statistically
significant benefits in the primary outcome of depression symptomatology and severity across the follow-up
period, as measured by a commonly used tool for the identification of depression (PHQ-9). The benefit was
most evident at 4 months and the magnitude of benefit was 1.9 points on the PHQ-9 scale, which equated
to a small to moderate clinical effect size (Cohen’s d= 0.32).40 By 12 months the between-group difference
was attenuated and was no longer statistically significant. The odds of no longer being depressed (defined
as a PHQ-9 score of < 10) at 4 months were increased twofold in the facilitated cCBT group compared with
minimally supported cCBT group (OR 2.05, 95% CI 1.23 to 3.42).
Turning to the range of secondary outcomes that were collected in the REEACT-2 trial, there was evidence
of statistically significant effects on the overall (including all time points) mean depression scores and
anxiety scores (as measured by the GAD-7; between-group difference 1.1, 95% CI 0.1 to 2.3; p= 0.037).
For somatoform complaints there was some evidence of a benefit, but the difference was not statistically
significant (PHQ-15 between-group difference 1.1, 95% CI 0.0 to 1.8; p= 0.051).
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When engagement with cCBT was monitored in the trial with reference to computer records, it was found
that there was enhanced uptake and use of programmes. Telephone facilitation, therefore, had the
anticipated effect of increasing engagement with computer-based technology. Nevertheless, very few
participants (only 19%) completed all five treatment sessions. As was found in the REEACT trial, the use of
computer sessions was quite low in the minimally supported treatment arm (with only 45% completing
the first session) than in the telephone-facilitated group (65%).
In summary, the main finding is therefore that, for the primary outcome of depression severity and
symptomatology, there was a clinically and statistically significant additional benefit across a range of
psychological outcomes when participants were offered a telephone-facilitated form of computerised
therapy in addition to usual GP care. This benefit was also seen in a range of secondary outcomes.
Telephone facilitation resulted in additional clinical improvements when compared with minimally
supported cCBT. The comparator arm represented an intervention that replicated cCBT as it is currently
offered in routine NHS services, and the additional technology of telephone facilitation was therefore
effective in improving clinical outcomes.
Summary of trial-based estimates of cost-effectiveness
The within-trial results of the economic analysis suggest that telephone facilitation resulted in increased
quality of life (QALYs) and reduced health-care costs (i.e. it was dominant). In a more conservative
sensitivity analysis, the scenario changed and telephone-facilitated cCBT was no longer dominant.
However, the additional benefit in terms of QALYs was incurred at an acceptable ratio to costs. In the
cost-effectiveness analysis, an ICER of £6933 per additional QALY for telephone facilitation was observed.
The addition of telephone facilitation was likely to be cost-effective at a £20,000 per QALY threshold.
Although the cost-effectiveness conclusions appear sensitive to the choice costs, the magnitude of the
differences between the two groups was relatively minor for both cost and QALY estimates in both
the scenarios. Hence, minor differences in the assumptions can lead to different cost-effectiveness
interpretations of either dominance or cost-effectiveness, and some caution should be exercised when
interpreting these results. However, under no scenario was telephone facilitation cost-ineffective
(> £30,000 per QALY) or dominated by minimally supported cCBT.
Discussion of main findings
The clinical results of the REEACT-2 trial are consistent with some increase in benefit that has been
observed in systematic reviews of computer-mediated cCBT.9 The addition of telephone facilitation based
on a manualised support programme enhanced the effectiveness of cCBT. Minimally supported cCBT
(such as is used in the NHS at present) was shown in the REEACT trial to be no more effective than usual
GP care. In the REEACT-2 trial, a more intensive telephone facilitation was added to cCBT, and this
resulted in statistically significant clinical benefit over and above usual GP care. This finding is important for
those who deliver or commission psychological services in primary care. cCBT is a commonly advocated
first-line low-intensity treatment option in UK primary care and the offer of this treatment without the
provision of telephone facilitation is, on average, unlikely to be of benefit to patients. By adding a level of
telephone facilitation that is structured and reinforces the content of CBT treatment sessions, engagement
with the programme and clinical outcomes are, on average, improved. The magnitude of this benefit was
small to moderate, and was broadly in line with other low-intensity psychological interventions for
depression that are delivered in primary care. A systematic review and meta-analysis by Cuijpers et al.41
has demonstrated that the magnitude of effect of primary care-based psychological interventions is, on
average, small to moderate (pooled effect size, Cohen’s d= 0.31, 95% CI 0.17 to 0.45) and the results of
the REEACT-2 trial are broadly in line with this body of research.41 In comparison with other estimates
of effect size obtained from developer-led trials, the magnitude of effect observed in REEACT-2 is smaller.
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It should be noted that REEACT-2 is a pragmatic trial, which recruited in primary care rather than specialist
cCBT services and was conducted independently of product developers. We would therefore expect that
the effect size would be smaller and more representative of the benefits expected under conditions of
routine care.
To date there have been only limited cost-effectiveness data relating to psychological therapies generally and
low-intensity therapies specifically.39 In relation to cCBT there are very few economic evaluations, and those
that do exist (e.g. Kaltenthaler et al.6 and Proudfoot et al.7) have been conducted alongside developer-led
trials framed in specialist services and with larger clinical effect sizes than were observed in the REEACT and
REEACT-2 trials. The REEACT and REEACT-2 trials represent the largest economic evaluations of cCBT to
date, and directly examine the cost-effectiveness of cCBT from the perspective of the UK NHS. The results of
the REEACT-2 trial-based economic evaluation indicate that telephone-supported cCBT is either dominant
(cost saving and more effective) or cost-effective within an acceptable threshold of willingness to pay. These
economic data will be of interest to decision-makers and those charged with the commissioning of services.
An important feature of the REEACT-2 trial is that we evaluated a free-to-use cCBT package that can be
accessed by UK NHS patients at no direct cost. There are a number of cCBT products and packages that
could be used in the NHS and that could have been trialled within the REEACT-2 trial. The rationale
for choosing MoodGYM was threefold. First, there was evidence of effect from developer-led trials,8
suggesting that MoodGYM had the potential to be effective in NHS services. Second, we have shown in
the REEACT trial that MoodGYM is not inferior to commercially developed cCBT products.12 Third, the
technology can be accessed at no direct cost to patients in the UK NHS and it had received cautious
support in earlier technology appraisals.6 The results of the REEACT-2 trial are therefore of relevance
to decision-makers as investment or commissioning of the use of cCBT will not require purchase of
commercially developed products.
There were limitations to the REEACT-2 trial. The first limitation is that we did not obtain a standardised
diagnosis of depression at the point of entry to the trial. Instead, we chose a more pragmatic method that
judged the presence of symptomatic depression in a more pragmatic way, according to scores on a
depression severity scale (the PHQ-9). We also noted that coexisting anxiety and somatoform complaints
were common. Although this might be a more heterogeneous population than that seen in efficacy
studies, it could be argued that the participants in the REEACT-2 trial were more representative of people
with common mental disorders seen in primary care. The level of severity of depression observed with a
PHQ-9 cut-off point of ≥ 10 is in line with moderate depression and previous research has shown that this
cut-off point is sensitive and specific in identifying people with clinically significant depression. The second
limitation is that the level of use of cCBT was quite low and was lower than that observed in developer-led
trials. It might be argued that higher levels of uptake and use might have produced larger and more
clinically significant effect sizes. However, we have noted that higher levels of uptake have generally
been observed in developer-led trials or studies for which there was intensive one-to-one input from a
psychological therapist with the therapist present at the time of delivery of the cCBT intervention.7
We would argue that the REEACT-2 trial represented an evaluation of a feasible model of cCBT and
low-intensity support that might more readily be delivered at scale within NHS primary care psychological
therapy services. The third limitation is the greater than planned level of loss to follow-up that was
observed in the REEACT-2 trial. We observed that 27% of participants were lost to follow-up at 4 months
and 26% of participants were lost to follow-up at 12 months. There was some evidence of differential
attrition, with levels of attrition between 3% and 5% higher in the minimally supported cCBT group.
The levels of loss to follow-up were, however, broadly in line with other primary care-based studies of
psychological interventions (e.g. King et al.42).
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Conclusion
Computerised CBT forms a core component of stepped psychological care in the UK primary care and
other health systems. We have previously found in the REEACT trial that minimally supported cCBT is
clinically ineffective and cost-ineffective and confers no additional benefit over usual GP care for
depression. In the REEACT-2 trial, a level of telephone-delivered facilitation was added to cCBT and
modest but statistically significant improvements were found in the primary outcome of the presence of
depression and other psychological symptoms. Telephone-facilitated cCBT was also cost-effective.
Implications for health care
l In this trial for primary care patients with moderate depression, telephone-facilitated cCBT was clinically
effective compared with minimally supported cCBT. Current models of care might usefully be
re-examined in the light of these findings with due consideration of the level of support that should
be offered alongside cCBT.
l Minimally supported cCBT (which is routinely offered in the NHS in many services) is ineffective and our
research suggests that outcomes may improve only when there is sufficient staff in place to support
this technology with guidance and facilitation by telephone. This can be offered by telephone
according to structured delivery manuals, and allows support to be offered at low intensity and
higher volume.
l Telephone-facilitated cCBT is likely to be cost saving or cost-effective to the NHS.
Recommendations for research
l The uptake and use of cCBT was not as high as expected. More research is needed to understand the
reasons for lower uptake, and more development is needed for cCBT products to further evolve such
that they are more acceptable to people with depression. This requires further research and innovation
at the human–computer interface.
l People with depression commonly have coexisting anxiety and somatoform complaints. Although some
benefits were observed in these symptoms, the cCBT materials did not specifically address these
problems. Further research and development is needed to ensure that cCBT products are able to
address coexisting common mental disorders within a single-treatment programme.
l cCBT is a form of self-help. It would be useful to know how cCBT compares to other forms of guided
self-help because computer-delivered therapy is not acceptable to a significant portion of patients.
Large-scale pragmatic trials of treatments such as bibliotherapy or telephone-based psychological
interventions are therefore needed.
l There is a need to examine comparative effectiveness and cost-effectiveness of facilitated cCBT and
traditional face-to-face therapy in head-to-head trials.
l All effectiveness studies should be framed in primary care and conducted by researchers other than
product developers.
l Studies should include measures of absenteeism/presenteeism and be powered to examine
explanatory variables.
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Appendix 1 Sources and details of unit costs
TABLE 35 Sources and details of key unit costs
Health-care costs Source Unit Cost (£) Extra information
Community care
GP
At surgery PSSRU 201343 Per hour 230.00
At surgery PSSRU 201343 Per consultation 44.85 Average appointment= 11.7 minutes
At home PSSRU 201343 Per hour 292.00
At home PSSRU 201343 Per consultation 113.88 Average appointment= 23.4 minutes
Telephone consultation PSSRU 201343 Per hour 230.00
Telephone consultation PSSRU 201343 Per consultation 27.22 Average appointment= 7.2 minutes
Nurse
At GP surgery PSSRU 201343 Per hour 40.00
At GP surgery PSSRU 201343 Per consultation 10.33 Average appointment= 15.5 minutes
District nurse PSSRU 201343 Per hour 48.00
District nurse PSSRU 201343 Per consultation 12.40 Average appointment= 15.5 minutes
Psychiatric nurse PSSRU 201343 Per hour 49.00
Psychiatric nurse PSSRU 201343 Per consultation 12.66 Average appointment= 15.5 minutes
Other
Counsellor PSSRU 201343 Per hour 48.00
Counsellor PSSRU 201343 Per consultation 44.00 Average appointment= 55 minutes
Social worker PSSRU 201343 Per hour 57.00
Social worker PSSRU 201343 Per consultation 52.50 Average appointment= 55 minutes
Occupational therapist PSSRU 201343 Per hour 34.00
Occupational therapist PSSRU 201343 Per consultation 17.00 Average appointment= 30 minutes
Home care worker PSSRU 201343 Per hour 20.00
Home care worker PSSRU 201343 Per consultation 10.00 Average appointment= 30 minutes
Community day care costs
Day care centre PSSRU 201343 Per session 38.00 Assumes 1 hour per session
Sheltered workshop PSSRU 201044 Per session 8.40 Assumes 1 hour per session, prices uprated
from 2010
Medication
Antidepressants BNF45 Per item 4.48 Assumes one prescription per month
Anxiolytics and
hypnotics
BNF45 Per item 4.28 Assumes one prescription per month
Propranolol BNF45 Per item 9.15 Assumes one prescription per month
Pregabalin BNF45 Per item 64.20 Assumes one prescription per month
Antipsychotics BNF45 Per item 13.25 Assumes one prescription per month
continued
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TABLE 35 Sources and details of key unit costs (continued )
Health-care costs Source Unit Cost (£) Extra information
Hospital inpatient
Mental health
Acute psychiatric ward PSSRU 201044 Per bed-day 333.00 Costs uprated from 2010
Psychiatric rehabilitation
ward
NHS reference
costs 201046
Per bed-day 334.01 Activity weighted average of HRGs related
to rehabilitation for psychiatric disorders.
Costs uprated from 2010
Psychiatric ICU PSSRU 201044 Per bed-day 650.10 Costs uprated from 2010
Non-mental health
Long-stay ward NHS reference
costs 201330
Per bed-day 915.92 Activity weighted average of all HRGs for
all elective/non-elective procedures
General medical ward NHS reference
costs 201330
Per bed-day 915.92 Activity weighted average of all HRGs for
all elective/non-elective procedures
Hospital outpatient
Mental health
Psychiatrist NHS reference
costs 201330
Per admission 221.00 Activity weighted average of psychiatric
outpatient visits
Clinical psychologist NHS reference
costs 201330
Per admission 191.00 Activity weighted average of psychology
outpatient visits
Non-mental health
A&E visit NHS reference
costs 201330
Per admission 117.00 Activity weighted average of all outpatient
A&E visits
Visit (excluding A&E) NHS reference
costs 201330
Per admission 108.00 Activity weighted average of all outpatient
HRGs, excluding A&E
Day hospital NHS reference
costs 201330
Per admission 108.00 Activity weighted average of all
outpatient HRGs
A&E, accident and emergency; BNF, British National Formulary; HRG, Healthcare Resource Group; ICU, intensive care unit;
PSSRU, Personal Social Services Research Unit.
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Appendix 2 Patient information leaflet
      
 
Participant Information Sheet 
REEACT-2: Computerised Cognitive Behaviour 
Therapy for Depression
 
 
  
We invite you to take part in a research study Contents 
Before you decide whether to take part, it is important for 
you to understand why the research is being done and 
what it will involve.  
Please take the time to read the following information 
carefully. Discuss it with friends and relatives if you wish. 
Take time to decide whether or not you wish to take part.  
You are free to decide whether or not to take part in this 
research. If you choose not to take part, this will not affect 
the care you get from your GP.  
Ask us if there is anything that is not clear or if you would 
like more information.  
Thank you for reading this information sheet. If you decide 
to take part please sign the consent form and post it back 
to us in the prepaid envelope provided.  
1 Why we are doing this study 
2 How the study works 
3 Why am I being asked to take 
part? 
4 What will happen to me if I 
take part?  
5 How is taking part in the study 
different from usual GP care?  
6 Possible benefits and 
disadvantages of taking part 
7 More information about taking 
part 
8 Contact for further 
information  
Important things you need to know 
If you have any questions about 
this study please talk to:  
<<Local researcher Name>> 
<<Address>> 
<<Tel>>  
 
 
 
 
How to contact us
We want to find out more about how computerised 
cognitive behaviour therapy (CBT) may help people 
suffering from depression.  
We are particularly interested in exploring whether 
providing telephone support to patients using 
computerised CBT has an added benefit to their health.  
Everyone involved in the research study will receive access 
to a computerised CBT programme.  
By asking you to complete some questionnaires before you 
start the programme and again at 4 months and 12 months 
after you enter into the study we hope to understand 
more about what helps.   
You can stop taking part in the study at any time, without 
giving a reason.
DOI: 10.3310/hta20890 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 89
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Brabyn et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
57
  
What are we studying?  
Depression causes misery to many people and is 
a major health problem in the UK.  The majority 
of people with depression receive care from their 
GP and never really see a specialist. However, 
lots of people experiencing depression would also 
like to receive a “talking treatment” (counselling 
or psychotherapy).  
 
What therapy are we looking at?  
Cognitive Behaviour Therapy (or ‘CBT’ for short) 
is an effective type of talking treatment that can 
help people who have depression. At present 
CBT is not always immediately available in the 
NHS. Recently, therapists have developed a form 
of CBT that can be delivered by computer, which 
might make it easier to access this form of 
treatment.  We call this “computerised CBT”.   
Computerised CBT is recommended by the 
National Institute for Clinical Excellence (NICE) 
for people experiencing depression, but we need 
more information about how best to support 
people who are using it.  
 
What do we hope to find out?  
At the moment there is some evidence that 
suggests people who are using computerised CBT 
may benefit from receiving additional support 
from a telephone support worker. The telephone 
support worker is able to help with any technical 
difficulties relating to the programme and may 
also help keep people motivated to continue 
using it.  
 
This study investigates if providing people with 
weekly telephone support whilst they use 
computerised CBT leads to an improvement in 
their symptoms of depression.  
 
 
 
 
How do we find out whether 
telephone support helps?  
We do this by setting up everyone who takes 
part in the study with access to a computerised 
CBT programme. We then randomly allocate 
people into one of two groups: one group 
receives weekly telephone support calls and the 
other group does not.   
 
How is it decided who gets 
telephone support? 
A computer will choose whether you will receive 
the telephone support calls – this is called 
‘randomisation’. This is a bit like rolling a dice to 
decide whether you receive telephone support or 
not. It means you have an equal chance of 
receiving the telephone support or not.  
 
The rest of this leaflet explains how you might be 
involved in our research study.  
 
  
 
1 
2 
3 
Why we are doing this study
Why am I being asked to take 
part?
How the study works
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Your GP is involved in the study and has 
identified you as suffering from depression. We 
hope to get 200 people with depression into the 
study to help us improve treatment. 
 
 
 
Enrolling you in the study 
If you are interested in taking part you will need 
to complete the enclosed consent form and 
return this to your local researcher in the prepaid 
envelope provided. You will then be contacted by 
the researcher who will check if you are eligible 
to take part in the study by asking you some brief 
questions.  
 
At this point you will also have the opportunity 
to raise with the researcher any questions you 
might have about the study. You do not have to 
enter the study unless you feel completely happy 
with what you are being asked to do.  
 
Collecting information  
If you are eligible to take part and you are happy 
to proceed with the study the researcher will 
then ask a series of questions relating to your 
health. The researcher can either ask you these 
questions over the telephone or we can arrange 
to meet you in person. These baseline questions 
will take about half an hour to complete.   
 
 Setting you up with computerised 
CBT 
Everyone who takes part in the study will receive 
access to a computerised CBT programme called 
Moodgym. This is available online and you can use 
it in your own home if you have internet access. If 
you do not have internet access at home you will 
be able to talk through with the researcher 
where else you may be able to use the 
programme.  
 
The programme is split into 6 sessions with each 
session taking about one hour to complete. You 
will be asked to work your way through the 
programme completing a session about once a 
week.  
 
After the initial baseline interview the researcher 
will provide you with a web address, username 
and password which will allow you access the 
Moodgym programme. You will then be able to 
start the computerised CBT straight away. The 
researcher will also be able to tell you whether 
you will be in the group that receives telephone 
support calls or not.  
 
Telephone support 
If you are in the telephone support group you will 
be contacted by one of the telephone support 
workers who work on the study. The telephone 
support worker will explain how they may be 
able to help you with the computerised CBT and 
will arrange a suitable time to call you on a 
weekly basis for up to 8 weeks.  
 
It is important that you are aware that the 
telephone support workers are not trained 
counsellors. They will provide technical and 
motivational support to help you benefit from the 
computer package. They will not be able to offer 
advice relating to your emotional health.  
 
If you are in the group without telephone support 
you will not receive regular telephone calls. You 
4 What will happen to me if I take part?  
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will however be provided with a free-phone 
helpline number to ring in case of any problems 
with the computer programme.   
 
Follow up 
Four months after you have entered into the 
study we will contact you again to ask you a 
further set of questions to see how you are 
feeling now. We will also do this 12 months after 
you have entered into the study.  
 
There are four options to choose from as to how 
you would like to complete the follow up 
questions for us:  
(1) the researcher can contact you and go 
through the questions with you over the 
telephone 
(2) we can provide you with a web address 
and password where you can answer the 
questions online 
(3) we can post you paper versions of the 
questions for you to complete with a 
prepaid envelope in which you can return 
them to us 
(4) we can arrange to meet you in person to 
go through the questions together 
 
You can let the researcher know how you would 
prefer to do the follow up questions.  
 
 
 
The main difference will be that you will be set up 
with a computerised CBT programme by your 
local researcher. The researcher will also want 
you to complete some questionnaires before you 
start the programme and at the follow up points 
at 4 and 12 months. If you are in the telephone 
supported group you will also receive weekly 
telephone calls from the telephone support 
worker.  
 
Whilst you are taking part in the study you will 
continue to be looked after by your GP, as 
normal. You can see your GP as often as you and 
he/she thinks necessary. No treatment will be 
withheld from you during the course of this 
study.  
 
 
  
 
What are the possible disadvantages 
and risks of taking part in REEACT-
2?  
Computerised CBT is a relatively new treatment 
for depression. At the moment there is still some 
uncertainty about how effective it is. It may be 
that you do not find this method of treatment 
helpful. At any point during the study you can 
stop using the programme without having to give 
a reason why. There are no known side effects of 
computerised CBT.   
 
 
 
What are the possible benefits of 
taking part in REEACT-2? 
We hope that you will be helped by receiving the 
computerised CBT programme, but this cannot 
be guaranteed. 
5 
6 
How is taking part in the study 
different from usual GP care?  
Possible benefits and 
disadvantages of taking part 
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
60
 By participating in this trial you may receive 
additional support to use the computerised CBT 
programme than might otherwise be available in 
your GP practice.  
 
 
 
Do I have to take part?  
It is up to you to decide whether or not to take 
part. We will describe the study and go through 
this information sheet with you. You are free to 
withdraw at any time, without giving a reason. 
This would not affect the standard or type of care 
you receive.  
 
Will I receive any payment for taking 
part?  
Unfortunately we are not able to offer any 
expenses or payments to patients who participate 
in the study. However, participants will be sent a 
goodwill gesture of £5 with the four- and 12-
month follow-up questionnaires.   
 
What happens if new information 
becomes available during the course 
of the study?  
Sometimes during a study, new information 
becomes available about the treatment being 
studied. If this happens, the research team will tell 
you and discuss whether you want to continue in 
the study. If you decide to stop taking part in the 
study your usual GP care will continue. If you 
decide to continue in the study you may be asked 
to sign an updated consent form. If we think you 
should withdraw from the study, we will explain 
the reasons and arrange for your care to 
continue.  
What happens when the study stops?  
Very occasionally a study is stopped early. If this 
happens, the reasons will be explained to you and 
arrangements made for your GP care to continue 
as usual.  
 
What if there is a problem?  
If you have a concern about any aspect of this 
study you should ask to speak to the researcher 
who will do their best to answer your questions 
<<insert local tel>>. Alternatively you could 
speak to the chief investigator Prof. Simon 
Gilbody (tel: XXXX). 
 
If you remain unhappy and wish to complain 
formally, the normal NHS complaints process is 
available to you.  
 
If you are harmed by taking part, or if you are 
harmed due to someone’s negligence, then you 
may be able to take legal action.  
 
What will happen to information 
about me collected during the study?  
All information will be held securely and in strict 
confidence.  We keep the information we collect 
about you separate from your personal details 
and we can only link this information together 
with a secure code. Only authorised members of 
the research team will have access to your 
information.  
 
We will use the information we collect to look at 
how best to help people using computerised 
7 More information about taking part 
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CBT. We will keep it for 20 years and then 
destroy it securely. We will destroy all contact 
information immediately after the end of the 
study.  
 
Involvement of your GP 
We will tell your GP that you are taking part in 
the study and inform them of your results on the 
initial screening questions we use to check if you 
are eligible to take part. No other questionnaire 
results will be given to your GP. There is space 
on the consent form for you to confirm that you 
are aware of this. We will also inform them 
whether you are receiving the telephone support 
calls or not.  
 
If we are worried that you are having thoughts 
about harming yourself, we may need to discuss 
these with your GP. We will of course discuss 
this with you.  
 
If you send us a questionnaire through the post 
or complete a questionnaire online and we are 
worried that you are having thoughts about 
harming yourself, we will let your GP know of 
our concerns.  
 
What will happen to the results of 
the study?  
When the study is completed, the results will be 
published in a health care journal so health care 
professionals can see the results. If published, 
your identity and personal details will be kept 
confidential. No named information about you 
will be published in any report about this study. 
We will also provide you with a summary of our 
findings from the study.  
  
Who is organising and funding the 
study?  
This trial is organised by the University of York. 
The funder is the Health Technology Assessment 
(HTA) programme.  
 
Who has reviewed the study?  
This trial has been reviewed an independent 
group of people, called the Research Ethics 
Committee, to protect your safety, rights, well 
being and dignity. The study has been given a 
favourable opinion by Bradford Research Ethics 
committee.  
 
 
 
If you have any questions regarding the study or 
how you might be involved further contact 
information can be found below.  
 
Local researcher 
<<name, address, tel, email>> 
 
Chief Investigator
 
 Thank you for taking the time to 
consider taking part in this study.  
 
 
8 Contact for further information  
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Appendix 3 Regression coefficients used for
cost-effectiveness analysis
TABLE 36 Costs
Base_Total_Costs Coefficient Standard error t-value p-value 95% CI
Telephone-facilitated cCBT –24.5895 159.8417 –0.15 0.878 –338 to 288.8209
age 0.337438 5.123713 0.07 0.947 –9.71153 to 10.3864
gender –110.986 216.7175 –0.51 0.611 –548.532 to 326.5595
anxiety_bl 1.205872 18.9265 0.06 0.949 –36.0859 to 38.49764
PHQ-9_S0_M0 63.33961 22.46457 2.82 0.005 19.21393 to 107.4653
Costs_Bl 1.623163 0.406401 3.99 0 0.817154 to 2.429172
Prev_Dep_None 110.5375 189.6738 0.58 0.56 –262.502 to 483.5772
Prev_Dep_Chron 121.0653 240.7702 0.5 0.615 –351.261 to 593.3917
_cons –498.323 413.9716 –1.2 0.229 –1310.73 to 314.0801
TABLE 37 Quality-adjusted life-years
QALY Coefficient Standard error t-value p-value 95% CI
Telephone-facilitated cCBT 0.003742 0.018268 0.2 0.838 –0.03226 to 0.039741
age –0.00097 0.00064 –1.51 0.133 –0.00224 to 0.000302
gender 0.029349 0.020611 1.42 0.16 –0.01198 to 0.070674
anxiety_bl –0.00286 0.002206 –1.29 0.197 –0.0072 to 0.001489
PHQ-9_S0_M0 –0.00376 0.002506 –1.5 0.135 –0.00871 to 0.001187
eq5d0 0.488292 0.050897 9.59 0 0.385847 to 0.590738
Prev_Dep_None 0.016942 0.01959 0.86 0.389 –0.02192 to 0.055807
Prev_Dep_Chron –0.08336 0.023284 –3.58 0 –0.12925 to –0.03747
_cons 0.531626 0.067896 7.83 0 0.397444 to 0.665807
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